BioLineRx (BLRX) 20-F 26 Mar 24 2023 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Dec. 31, 2023 shares
Document Information [Line Items]
Document Type	20-F
Entity Registrant Name	BioLineRx Ltd.
Entity Central Index Key	0001498403
Document Period End Date	Dec. 31, 2023
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Amendment Flag	false
Document Registration Statement	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Document Accounting Standard	International Financial Reporting Standards
Document Financial Statement Error Correction [Flag]	false
Entity's Reporting Status Current	Yes
Entity a Voluntary Filer	No
Entity Incorporation State Country Code	L3
Contact Personnel Fax Number	972 (8) 642-9101
Entity Address, Address Line One	2 HaMa’ayan Street
Entity Address, City or Town	Modi’in
Entity Address, Postal Zip Code	7177871
Entity Address, Country	IL
Entity Interactive Data Current	Yes
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Entity Common Stock, Shares Outstanding	1,086,589,165
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity File Number	001-35223
Entity a Well-known Seasoned Issuer	No
ICFR Auditor Attestation Flag	true
Auditor Name	Kesselman & Kesselman
Auditor Location	Tel Aviv, Israel
Auditor Firm ID	1309
Business Contact [Member]
Document Information [Line Items]
Contact Personnel Name	Philip A. Serlin
Contact Personnel Email Address	phils@biolinerx.com
Entity Address, Address Line One	2 HaMa’ayan Street
Entity Address, City or Town	Modi’in
Entity Address, Postal Zip Code	7177871
City Area Code	972
Local Phone Number	642-9100
Entity Address, Country	IL

CONSOLIDATED STATEMENTS OF FINA

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS
Cash and cash equivalents	$ 4,255	$ 10,587
Short-term bank deposits	38,739	40,495
Trade receivables	358	0
Prepaid expenses	1,048	198
Other receivables	830	721
Inventory	1,953	0
Total current assets	47,183	52,001
NON-CURRENT ASSETS
Property and equipment, net	473	726
Right-of-use assets, net	1,415	1,772
Intangible assets, net	14,854	21,885
Total non-current assets	16,742	24,383
Total assets	63,925	76,384
CURRENT LIABILITIES
Current maturities of long-term loans	3,145	1,542
Contract liabilities	12,957	0
Accounts payable and accruals:
Trade	10,869	6,966
Other	3,353	1,744
Current maturities of lease liabilities	528	427
Total current liabilities	30,852	10,679
NON-CURRENT LIABILITIES
Warrants	11,932	4,509
Long-term loans, net of current maturities	6,628	8,626
Lease liabilities	1,290	1,729
Total non-current liabilities	19,850	14,864
COMMITMENTS AND CONTINGENT LIABILITIES
Total liabilities	50,702	25,543
EQUITY
Ordinary shares	31,355	27,100
Share premium	355,482	338,976
Warrants	1,408	1,408
Capital reserve	17,000	14,765
Other comprehensive loss	(1,416)	(1,416)
Accumulated deficit	(390,606)	(329,992)
Total equity	13,223	50,841
Total liabilities and equity	$ 63,925	$ 76,384

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Profit or loss [abstract]
REVENUES	$ 4,800	$ 0	$ 0
COST OF REVENUES	(3,692)	0	0
GROSS PROFIT	1,108	0	0
RESEARCH AND DEVELOPMENT EXPENSES	(12,519)	(17,629)	(19,466)
SALES AND MARKETING EXPENSES	(25,270)	(6,462)	(1,003)
GENERAL AND ADMINISTRATIVE EXPENSES	(6,310)	(5,066)	(4,308)
IMPAIRMENT OF INTANGIBLE ASSETS	(6,703)	0	0
OPERATING LOSS	(49,694)	(29,157)	(24,777)
NON-OPERATING INCOME (EXPENSES), NET	(10,819)	5,670	(1,830)
FINANCIAL INCOME	2,068	694	559
FINANCIAL EXPENSES	(2,169)	(2,158)	(1,006)
LOSS AND COMPREHENSIVE LOSS	$ (60,614)	$ (24,951)	$ (27,054)
LOSS PER ORDINARY SHARE – BASIC	$ (0.06)	$ (0.03)	$ (0.04)
LOSS PER ORDINARY SHARE – DILUTED	$ (0.06)	$ (0.03)	$ (0.04)
WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATION OF LOSS PER ORDINARY SHARE	963,365,525	773,956,973	662,933,695

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) $ in Thousands	Ordinary shares [Member]	Share premium [Member]	Warrants [Member]	Capital reserve [Member]	Other comprehensive loss [Member]	Accumulated deficit [Member]	Total
BALANCE at Dec. 31, 2020	$ 9,870	$ 279,241	$ 0	$ 12,322	$ (1,416)	$ (277,987)	$ 22,030
CHANGES IN
Issuance of share capital and warrants, net	8,956	40,476	975	0	0	0	50,407
Warrants exercised	2,235	18,967	0	0	0	0	21,202
Employee stock options exercised	5	41	0	(39)	0	0	7
Employee stock options expired	0	621	0	(621)	0	0	0
Share-based compensation	0	0	0	1,495	0	0	1,495
Comprehensive loss for the year	0	0	0		0	(27,054)	(27,054)
BALANCE at Dec. 31, 2021	21,066	339,346	975	13,157	(1,416)	(305,041)	68,087
CHANGES IN
Issuance of share capital and warrants, net	6,029	(1,007)	433	0	0	0	5,455
Employee stock options exercised	5	14	0	(14)	0	0	5
Employee stock options expired	0	623	0	(623)	0	0	0
Share-based compensation	0	0	0	2,245	0	0	2,245
Comprehensive loss for the year	0	0	0		0	(24,951)	(24,951)
BALANCE at Dec. 31, 2022	27,100	338,976	1,408	14,765	(1,416)	(329,992)	50,841
CHANGES IN
Issuance of share capital and warrants, net	3,242	10,847	0	0	0	0	14,089
Warrants exercised	1,000	5,559	0	0	0	0	6,559
Employee stock options exercised	13	45	0	(31)	0	0	27
Employee stock options expired	0	55	0	(55)	0	0	0
Share-based compensation	0	0	0	2,321	0	0	2,321
Comprehensive loss for the year	0	0	0	0	0	(60,614)	(60,614)
BALANCE at Dec. 31, 2023	$ 31,355	$ 355,482	$ 1,408	$ 17,000	$ (1,416)	$ (390,606)	$ 13,223

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
CASH FLOWS - OPERATING ACTIVITIES
Loss	$ (60,614)	$ (24,951)	$ (27,054)
Adjustments required to reflect net cash used in operating activities (see appendix below)	38,006	(1,289)	3,481
Net cash used in operating activities	(22,608)	(26,240)	(23,573)
CASH FLOWS - INVESTING ACTIVITIES
Investments in short-term deposits	(47,588)	(44,000)	(78,000)
Maturities of short-term deposits	49,329	48,322	39,873
Purchase of property and equipment	(116)	(131)	(97)
Purchase of intangible assets	(181)	(185)	0
Net cash provided by (used in) investing activities	1,444	4,006	(38,224)
CASH FLOWS - FINANCING ACTIVITIES
Issuance of share capital and warrants, net of issuance costs	14,089	14,359	50,407
Exercise of warrants	2,928	0	10,907
Employee stock options exercised	27	5	7
Proceeds from long-term loan, net of issuance costs	0	9,126	0
Repayments of loans	(1,543)	(2,832)	(3,376)
Repayments of lease liabilities	(445)	(220)	(196)
Net cash provided by financing activities	15,056	20,438	57,749
DECREASE IN CASH AND CASH EQUIVALENTS	(6,108)	(1,796)	(4,048)
CASH AND CASH EQUIVALENTS - BEGINNING OF YEAR	10,587	12,990	16,831
EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS	(224)	(607)	207
CASH AND CASH EQUIVALENTS - END OF YEAR	4,255	10,587	12,990
Income and expenses not involving cash flows:
Depreciation and amortization	1,384	654	703
Exchange differences on cash and cash equivalents	224	607	(207)
Fair value adjustments of warrants	11,054	(6,425)	1,936
Share-based compensation	2,321	2,245	1,495
Interest and exchange differences on short-term deposits	15	(672)	(262)
Interest on loans	1,148	1,117	301
Warrant issuance costs	0	171	0
Exchange differences on lease liabilities	(42)	(224)	55
Intangible assets impairment	6,703	0	0
Total income and expense not involving cash flows	22,807	(2,527)	4,021
Changes in operating asset and liability items:
Increase in trade receivables	(358)	0	0
Increase in inventory	(1,953)	0	0
Decrease (increase) in prepaid expenses and other receivables	(959)	(650)	24
Increase (decrease) in accounts payable and accruals	5,512	1,888	(564)
Increase in contract liabilities	12,957	0	0
Total Change in operating asset and liability	15,199	1,238	(540)
Total Adjustments required to reflect net cash used in operating activities	38,006	(1,289)	3,481
Supplementary information on investing and financing activities not involving cash flows:
Supplemental information on interest received in cash	2,020	342	138
Supplemental information on interest paid in cash	1,111	593	682
Changes in right-of-use asset and lease liabilities	149	706	183
Warrant issuance costs	0	262	0
Purchase of property and equipment	0	28	0
Fair value of exercised warrants (portion related to accumulated fair value adjustments)	$ 3,631	$ 0	$ 10,295

GENERAL INFORMATION

GENERAL INFORMATION	12 Months Ended
	Dec. 31, 2023
Disclosure of general information [Abstract]
GENERAL INFORMATION	NOTE 1 – GENERAL INFORMATION a. General BioLineRx Ltd. (“BioLineRx”), headquartered in Modi’in, Israel, was incorporated and commenced operations in April 2003. BioLineRx and its subsidiaries (collectively, the “Company”) are engaged in the development (primarily in clinical stages) and commercialization of therapeutics, with a focus on the fields of oncology and hematology. The Company’s American Depositary Shares (“ADSs”) are traded on the NASDAQ Capital Market, and its ordinary shares are traded on the Tel Aviv Stock Exchange (“TASE”). Each ADS represents 15 ordinary shares. The Company has two substantially wholly owned subsidiaries: (i) BioLineRx USA, Inc., incorporated in the U.S., and engaged in commercialization activities associated with the launch of motixafortide for stem-cell mobilization in the U.S.; and (ii) Agalimmune Ltd., incorporated in the United Kingdom, and engaged in clinical development activities with a focus on the field of immuno-oncology. In December 2023, the Company made a decision to terminate the development of AGI-134, the principal asset of Agalimmune Ltd., effective March 15, 2024 (see Note 9). In September 2023, the U.S. Food and Drug Administration (“FDA”) approved motixafortide in stem cell mobilization for autologous transplantation for multiple myeloma patients, and the Company has begun to independently commercialize motixafortide in the U.S. b. Israel-Hamas war On October 7, 2023, an unprecedented invasion was launched against Israel from the Gaza Strip by terrorists from the Hamas terrorist organization that infiltrated Israel’s southern border and other areas within the country, attacking civilians and military targets while simultaneously launching extensive rocket attacks on the Israeli civilian population. These attacks resulted in extensive deaths, injuries and the kidnapping of civilians and soldiers. In response, the Security Cabinet of the State of Israel declared war against Hamas, with commencement of a military campaign against the terrorist organization, in parallel to its continued rocket and terror attacks. In addition, Hezbollah, an Islamist terrorist group that controls large portions of southern Lebanon, has attacked military and civilian targets in Northern Israel, to which Israel has responded. To date, the State of Israel continues to be at war with Hamas and in an armed conflict with Hezbollah. The Company’s headquarters and principal development operations are located in the State of Israel. In addition, most of its key employees, officers and directors are residents of Israel. The ongoing war with Hamas has not, to date, materially impacted the Company’s business or operations. Furthermore, the Company does not expect any disruption to its programs or operations as a result of this situation. Nevertheless, at this time, it is not possible to predict the intensity or duration of Israel’s war against Hamas, nor how this conflict will ultimately affect the Company’s ongoing business and operations, nor Israel’s economy in general. c. Going concern The Company has incurred accumulated losses in the amount of $391 million through December 31, 2023, and it expects to continue incurring losses and negative cash flows from operations until its product or products reach commercial profitability. As mentioned in Note 3, Company management monitors rolling forecasts of the Company’s liquidity reserves on the basis of anticipated cash flows and seeks to maintain liquidity balances at levels that are sufficient to meet its needs. Management believes that the Company’s current cash and other resources will be sufficient to fund its projected cash requirements into 2025. The execution of an independent commercialization plan for motixafortide in the U.S. implies an increased level of expenses prior to and following launch of the product, as well as uncertainty regarding the timing of commercial profitability. Therefore, the Company’s cash flow projections are subject to various risks and uncertainties concerning their fulfilment, and these factors and the risks inherent in the Company’s operations indicate that a material uncertainty exists that may cast significant doubt (or raise substantial doubt as contemplated by PCAOB standards) on the Company’s ability to continue as a going concern. These consolidated financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. Management’s plans include the independent commercialization of the Company’s product, as aforementioned, and, if and when required, raising capital through the issuance of debt or equity securities, or capital inflows from strategic partnerships. There are no assurances, however, that the Company will be successful in obtaining the level of financing needed for its operations. If the Company is unsuccessful in commercializing its products and/or raising capital, it may need to reduce activities, or curtail or cease operations. d. Approval of consolidated financial statements The consolidated financial statements of the Company for the year ended December 31, 2023 were approved by the Board of Directors on March 25, 2024, and signed on its behalf by the Chairman of the Board, the Chief Executive Officer and the Chief Financial Officer.

MATERIAL ACCOUNTING POLICIES

MATERIAL ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2023
Disclosure of significant accounting policies [Abstract]
MATERIAL ACCOUNTING POLICIES	NOTE 2 – MATERIAL ACCOUNTING POLICIES a. Basis of presentation The Company’s consolidated financial statements as of December 31, 2022 and 2023, and for each of the three years in the period ended December 31, 2023, have been prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”). The material The consolidated financial statements have been prepared on the basis of historical cost, subject to adjustment of warrant liabilities to their fair value through profit or loss. The preparation of financial statements in conformity with IFRS requires management to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity and expenses, as well as the related disclosures of contingent assets and liabilities, in the process of applying the Company’s accounting policies. Actual results could differ from those estimates. Areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are material b. Functional and reporting currency The functional and reporting currency in these financial statements is the U.S. dollar (“dollar”, “USD” or “$”), which is the primary currency of the economic environment in which the Company operates. Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at year-end exchange rates are generally recognized in profit or loss. c. Inventory Inventory is measured at the lower cost or net realizable value. The cost of inventories includes purchase costs, packaging and labeling costs, and other costs incurred in bringing the inventories to their present location and condition. Net realizable value is the estimated selling price of the inventories in the ordinary course of business, less the estimated costs necessary to make the sale. Pre-launch inventory is held as an asset when there is a high probability of regulatory approval for the product, see Note 1a. Before that point, a provision is made against the value to its recoverable amount; the provision is then reversed at the point when regulatory approval is received. Inventory is written down for estimated obsolescence based upon management assumptions about future demand, expiration due date and market conditions. d. Property and equipment Property and equipment are stated at historical cost less depreciation. Historical cost includes expenditures that are directly attributable to acquisition of the items. Assets are depreciated by the straight-line method over the estimated useful lives of the assets, provided that Company management believes the residual values of the assets to be negligible, as follows: % Computers and communications equipment 33 Office furniture and equipment 6 Laboratory equipment 15 Leasehold improvements are amortized by the straight-line method over the shorter of the lease term or the estimated useful life of the improvements. e. Intangible assets The Company applies the cost method of accounting for initial and subsequent measurements of intangible assets. Under this method of accounting, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses. Intellectual property The Company recognizes in its financial statements intellectual property developed by the Company to the extent that the conditions stipulated in paragraph o. below are met. Intellectual property acquired by the Company is initially measured at cost. Intellectual property used by the Company for development purposes and not yet generating revenues is not amortized and is tested annually for impairment. See g. below. Computer software Acquired computer software licenses are capitalized based on the costs incurred to acquire and bring to use the specific software. These costs are amortized over the estimated useful lives of the software (5 years). f. Impairment of non-financial assets Impairment of intellectual property is required when the Company decides to terminate or suspend the development of a project based on such intellectual property. In addition, the Company performs impairment reviews on an annual basis, or more frequently if events or changes in circumstances indicate a potential impairment. Property and equipment, as well as computer software, are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized equal to the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs to sell and the asset’s value in use to the Company. See Note 9 for information about an impairment loss recorded in 2023 in connection with the decision to terminate the AGI-134 project. g. Warrants Receipts in respect of warrants are classified as equity to the extent that they confer the right to purchase a fixed number of shares for a fixed exercise price. In the event that the exercise price or the numbers of shares to be issued are not deemed to be fixed, the warrants are classified as a non-current derivative financial liability. This liability is initially recognized at its fair value on the date the contract is entered into and subsequently accounted for at fair value at each reporting date. The fair value changes are charged to non-operating income and expense on the statement of comprehensive loss. Issuance costs allocable to warrants classified as a liability are also recorded as non-operating expense on the statement of comprehensive loss. h. Borrowings Borrowings are initially recognized at fair value, net of transaction costs incurred. Borrowings are subsequently measured at amortized cost. Any difference between the proceeds (net of transaction costs) and the redemption amount is recognized in profit or loss over the period of the borrowings using the effective interest method. With respect to long-term loans (see Note 11), a financial liability is recognized for each tranche upon drawdown. Upon initial recognition, the effective interest rate is calculated by estimating the future cash flows, including loan principal repayments, interest and royalties. The royalty feature does not meet the definition of a derivative, is not classified separately, and is not measured separately, since it is an integral part of the loan terms and conditions and cannot be transferred or settled separately from the loan. Determining the weighted effective interest rate requires certain judgments and estimations regarding the timing and amount of the Company’s future revenues. The loans are subsequently measured at amortized cost. Furthermore, revisions to the estimated amounts or timing of future cash flows, if necessary, may result in an adjustment of the amortized cost of the loan to reflect the present value of actual and revised estimated contractual cash flows, discounted using the original effective interest rate. This adjustment will be recognized in profit or loss as financial income or expense. Borrowings are classified as current liabilities unless the Company has an unconditional right to defer settlement of the liability for at least 12 months subsequent to the reporting period. i. Revenues The Company accounts for contract revenue in accordance with IFRS 15, “Revenue from Contracts with Customers.” IFRS 15 introduces a five-step model for recognizing revenue from contracts with customers, as follows: • identify the contract with a customer; • identify the performance obligations in the contract; • determine the transaction price; • allocate the transaction price to the performance obligations in the contract; and • recognize revenue when (or as) the entity satisfies a performance obligation. Revenues from selling products In September 2023, the FDA approved motixafortide in stem cell mobilization for autologous transplantation for multiple myeloma patients, and shortly thereafter, the Company began to independently commercialize motixafortide in the U.S. The Company sells products mainly to wholesale distributors. Gross revenues are recognized at a point in time when control over the product is transferred to the distributors (upon delivery), at the gross selling price. The net revenues reflect gross revenues, reduced by amounts attributable to distributor fees, as well as accruals of chargebacks, rebates and returns. The specific considerations the Company uses in estimating these amounts relating to variable consideration are as follows: 1. Distribution fees - The Company pays distribution fees to its three main distributors. The distribution fees are paid based on contractually determined rates from the gross consideration. When the service is received and the products sold to distributors, it is recognized as a reduction of revenues in the period the related revenues from the sale of products are recognized. 2. Rebates and patient discount programs - The Company offers various rebate and patient discount programs, which result in discounted prescriptions to qualified patients. The Company estimates the allowance for these rebates, based on the estimated utilization of the rebate and discount programs, at the time the revenues are recognized. These estimates are recognized as a reduction of revenues. 3. Product returns - The Company offers customers a right of return as part of the distributor agreements. The Company estimates the amount of product sales that may be returned by its customers and records this estimate as a reduction of revenues at the time of sale, based on estimates of product returns based on its own sales information, its visibility into the inventory remaining in the distribution channel, and product dating. Revenues from licensing agreement According to IFRS 15, performance obligations are a promise to provide a distinct good or service or a series of distinct goods or services. Goods and services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. A good or service promised to a customer is distinct if the customer can benefit from the good or service, either on its own or together with other resources that are readily available to the customer, and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. IFRS 15 defines the ‘Transaction Price’ as the amount of consideration to which the entity expects to be entitled in exchange for transferring the promised goods or services to a customer. In accordance with IFRS 15, the Company identified a number of performance obligations (components) in the contract – in respect of which revenue will be recognized separately for each component, See Note 16. The following assumptions were taken into account, as part of the revenue recognition process: 1) Development milestones: Variable payments, contingent on achieving additional milestones, are included in the transaction price based on the most likely amount method. Amounts included in the transaction price are recognized only when it is highly probable that a material 2) Sales-based royalties and sales-based milestones are recognized as the related sale occurs, due to the specific exception of IFRS 15 for sales-based royalties from licensing of intellectual properties. For more information, see Note 16. j. Research and development expenses Research expenses are charged to profit or loss as incurred. As of December 31, 2023, the Company has not yet capitalized development expenses. k. Share-based payments The Company operates an equity-settled, share-based compensation plan, under which it grants equity instruments (options, restricted stock units and performance stock units) of the Company as additional consideration for services from employees and service providers. The fair value of the employee services received in exchange for the grant of the equity instruments is recognized as an expense. The total amount to be expensed is determined by reference to the fair value of the equity instruments granted including any market performance conditions (for example, the Company’s share price). Non-market performance and service conditions are included in assumptions about the number of equity instruments that are expected to vest. Performance stock unit expenses are recognized only if it is probable that the performance condition will be achieved. l. Loss per share 1) Basic The basic loss per share is calculated by dividing the loss attributable to the holders of ordinary shares by the weighted average number of ordinary shares outstanding during the year. 2) Diluted The diluted loss per share is calculated by adjusting the weighted average number of outstanding ordinary shares, assuming conversion of all dilutive potential shares. The Company’s dilutive potential shares consist of warrants issued to investors, as well as equity instruments granted to employees and service providers. The dilutive potential shares were not taken into account in computing loss per share in 2021, 2022 and 2023, as their effect would have been anti-dilutive. The calculation of diluted loss per share as of December 31, 2023 does not include 153,154,860 and 431,954,719 of shares underlying options, and shares underlying warrants, respectively, because the effect would be anti-dilutive. m. Leases The Company’s leases include property and motor vehicle leases. At the commencement date, the Company measures the lease liability at the present value of the lease payments that are not paid at that date. Simultaneously, the Company recognizes a right-of-use asset in the amount of the lease liability. Since the interest rate implicit in the lease cannot be readily determined, the Company uses the Company’s incremental borrowing rate. The lease term is the non-cancellable period for which the Company has the right to use an underlying asset, together with both the periods covered by an option to extend the lease, if the Company is reasonably certain to exercise that option, and periods covered by an option to terminate the lease, if the Company is reasonably certain not to exercise that option. After the commencement date, the Company measures the right-of-use asset applying the cost model, less any accumulated depreciation and any accumulated impairment losses and adjusted for any remeasurement of the lease liability. Assets are depreciated by the straight-line method over the estimated useful lives of the right of use assets or the lease period, whichever is shorter, as follows: Years Property 11 Motor vehicles 3 n. New International Financial Reporting Standards, amendments to standards and new interpretations: Classification of Liabilities as Current or Non-Current (Amendment to IAS 1) The narrow-scope amendments to IAS 1, “Presentation of Financial Statements,” clarify that liabilities are classified as either current or noncurrent, depending on the rights that exist at the end of the reporting period. Classification is unaffected by the entity’s expectations or events after the reporting date (e.g., the receipt of a waiver or a breach of covenant). The amendments also clarify what IAS 1 means when it refers to the ‘settlement’ of a liability. The amendments could affect the classification of liabilities, particularly for entities that previously considered management’s intentions to determine classification and for some liabilities that can be converted into equity. They must be applied retrospectively in accordance with the normal requirements in IAS 8, “Accounting Policies, Changes in Accounting Estimates and Errors.” The amendment should be applied retrospectively for annual periods beginning on or after January 1, 2024. Earlier application is permitted. The adoption of the amendment is expected to have a material impact on the Company’s financial statements as, effective January 1, 2024, the Company’s warrant liabilities will be classified in current liabilities. Deferred Tax Related to Assets and Liabilities Arising from a Single Transaction (Amendment to IAS 12) The amendment requires companies to recognize deferred tax on transactions that, on initial recognition, give rise to equal amounts of taxable and deductible temporary differences, and will require the recognition of additional deferred tax assets and liabilities. The amendment should be applied to transactions that occur on or after the beginning of the earliest comparative period presented. In addition, entities should recognize deferred tax assets (to the extent that it is probable that they can be utilized) and deferred tax liabilities at the beginning of the earliest comparative period for all deductible and taxable temporary differences associated with right-of-use assets and lease liabilities, decommissioning, restoration and similar liabilities, and the corresponding amounts recognized as part of the cost of the related assets. The adoption of the amendment had no material impact on the Company’s financial statements. Material accounting Policies (Amendment to IAS 1) The amendments change the requirements in IAS 1 with regard to disclosure of accounting policies. The amendments require entities to disclose their material rather than their significant accounting policies. Accounting policy information is material if, when considered together with other information included in an entity’s financial statements, it can reasonably be expected to influence decisions that the primary users of general-purpose financial statements make on the basis of those financial statements. The supporting paragraphs in IAS 1 are also amended to clarify that accounting policy information that relates to immaterial transactions, other events or conditions is immaterial and need not be disclosed. Accounting policy information may be material because of the nature of the related transactions, other events or conditions, even if the amounts are immaterial. However, not all accounting policy information relating to material transactions, other events or conditions is itself material. These financial statements are prepared in accordance with the amendments to IAS 1 as they were effective for annual periods beginning on January 1, 2023.

FINANCIAL INSTRUMENTS AND FINAN

FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT	12 Months Ended
	Dec. 31, 2023
Disclosure of detailed information about financial instruments [abstract]
FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT	NOTE 3 – FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT Based on assessments by Company management, the Company’s exposure to credit risk as of December 31, 2023, is immaterial (see Note 3b). The activities of the Company expose it to market risk, primarily as a result of currency risk. The Company’s Finance Department is responsible for carrying out risk management activities in accordance with policies approved by its Board of Directors. In this regard, the Finance Department identifies, defines and assesses financial risk in close cooperation with other Company departments. The Board of Directors provides written guidelines for overall risk management, as well as written policies dealing with specific areas, such as exchange rate risk, interest rate risk, credit risk, use of financial instruments and investment of excess cash. a. Market risk 1) Concentration of currency risk The Company’s activities are partly denominated in non-dollar currencies (primarily the New Israeli Shekel, or “NIS,” and the Euro), which exposes the Company to risks resulting from changes in exchange rates. The effect of fluctuations in various exchange rates on the Company’s income and equity is as follows: December 31, 2023 Income (loss) Value on Income (loss) Sensitive instrument 10% increase 5% increase balance sheet 5% decrease 10% decrease in USD thousands NIS-linked balances: Cash and cash equivalents (132 ) (69 ) 1,457 77 162 Short term deposit (251 ) (131 ) 2,758 145 306 Other receivables (31 ) (16 ) 344 18 38 Trade payables 243 127 (2,670 ) (141 ) (297 ) Other payables 169 89 (1,853 ) (98 ) (207 ) Total NIS-linked balances (2 ) 0 36 1 2 Euro-linked trade payables (117 ) (61 ) (1,283 ) 67 142 Total (119 ) (61 ) (1,247 ) 68 144 December 31, 2022 Income (loss) Value on Income (loss) Sensitive instrument 10% increase 5% increase balance sheet 5% decrease 10% decrease in USD thousands NIS-linked balances: Cash and cash equivalents (416 ) (218 ) 4,573 241 508 Other receivables (66 ) (34 ) 721 38 80 Trade payables 38 20 (416 ) (22 ) (46 ) Other payables 114 60 (1,257 ) (66 ) (140 ) Total NIS-linked balances (330 ) (172 ) 3,621 191 402 Euro-linked trade payables (144 ) (76 ) (1,590 ) 84 177 Total (474 ) (248 ) 2,031 275 579 The Company also maintains cash and cash equivalent balances in other currencies in amounts that are not material. Set forth below is information on the linkage of monetary items: December 31, 2022 December 31, 2023 Dollar NIS Other currencies Dollar NIS Other Currencies USD in thousands USD in thousands Assets: Current assets: Cash and cash equivalents 5,685 4,573 329 2,768 1,457 30 Short term bank deposits 40,495 - - 35,981 2,758 - Other receivables - 721 - 480 350 - 46,180 5,294 329 39,229 4,565 30 Liabilities: Current liabilities: Current maturities of long-term loans 1,542 - - 3,145 - - Accounts payable and accruals: Trade 4,359 416 2,191 6,663 2,670 1,536 Other 487 1,257 - 1,500 1,853 - Non-current liabilities Long-term loans, net of current maturities 8,626 - - 6,628 - - 15,014 1,673 2,191 17,936 4,523 1,536 Net balance 31,166 3,621 (1,862 ) 21,293 42 (1,506 ) 2) Fair value of financial instruments As of December 31, 2023, the financial instruments of the Company consist of non-derivative assets and liabilities (primarily working capital items, deposits, and current and long-term loans), as well as warrants classified as a liability. With regard to non-derivative assets and liabilities, given their nature, the fair value of the financial instruments included in working capital is generally close or identical to their carrying amount. With regard to the warrants classified as a non-current financial liability, see Note 12c. With regard to long-term loans, see Note 11. 3) Exposure to market risk and management thereof In the opinion of Company management, the market risk to which the Company is exposed is primarily related to currency risk exposure, as mentioned above. Additionally, Company management does not consider the interest rate risk mentioned in paragraph 4 below to be material. 4) Interest rate risk Company management does not consider interest rate risk to be material, as the Company holds deposits whose fair value and/or cash flows are not materially affected by changes in interest rates. b. Credit risk Credit risk is managed at the Company level. These risks relate to cash and cash equivalents, bank deposits trade receivables, and other receivables. The Company’s cash, cash equivalents and short-term bank deposits at December 31, 2022, and 2023 were deposited with highly rated major Israeli and U.S. banks. In the Company’s opinion, the credit risk associated with these balances is remote. The Company considers its maximum exposure to credit risk to be as follows: December 31, 2022 2023 in USD thousands Assets: Cash and cash equivalents 10,587 4,255 Short-term bank deposits 40,495 38,739 Trade receivables - 358 Other receivables 721 830 Total 51,803 44,182 c. Liquidity risk Company management monitors rolling forecasts of the Company’s liquidity reserves on the basis of anticipated cash flows and seeks to maintain the liquidity balances at a level that is sufficient to meet its needs. Although the Company has succeeded in generating revenues from a number of out-licensing transactions, and has recently launched commercialization of its lead program, motixafortide, in the last quarter of 2023, it cannot determine with reasonable certainty if and when it will become profitable on a current basis. Management believes that the Company’s current cash and other resources will be sufficient to fund its projected cash requirements into 2025. However, in the event that the Company does not begin to generate sustainable cash flows from its operating activities in the future, the Company will need to carry out significant cost reductions and/or raise additional funding. See also Note 1c regarding the material uncertainty that may cast significant doubt about the Company’s ability to continue as a going concern. d. Fair value of financial instruments The different levels of valuation of financial instruments are defined as follows: Level 1 Quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 Inputs, other than quoted prices included within level 1 that are observable for the asset or liability, either directly (as prices) or indirectly (derived from prices). Level 3 Inputs for the asset or liability that are not based on observable market data (unobservable inputs). The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk, in its assessment of fair value. The fair value of the financial instruments included in the working capital of the Company, as well as the long-term loan, is usually identical or close to their carrying value. The fair value of the warrants is based on Level 3 measurements. The fair value of the warrants, calculated based on the Black-Scholes model, was $11,932,000 as of December 31, 2023. For more information on the parameters used to value the warrants, see Note 12c. e. Changes in financial liabilities with cash flows included in financing activities Long-term loans Warrants Total in USD thousands Balance as of January 1, 2021 5,832 10,218 16,050 Changes during the year 2021: Principal and interest payments (3,814 ) - (3,814 ) Share premium resulting from exercise of warrants (10,295 ) (10,295 ) Amounts recognized through profit and loss 739 1,936 2,675 Balance as of December 31, 2021 2,757 1,859 4,616 Changes during the year 2022: Net proceeds 9,126 9,075 18,201 Principal and interest payments (3,177 ) - (3,177 ) Amounts recognized through profit and loss 1,462 (6,425 ) (4,963 ) Balance as of December 31, 2022 10,168 4,509 14,677 Changes during the year 2023: Principal payments or received (1,543 ) - (1,543 ) Amounts recognized through profit and loss 1,148 11,054 12,202 Share premium resulting from exercise of warrants - (3,631 ) (3,631 ) Balance as of December 31, 2023 9,773 11,932 21,705 f. Fair value measurement of warrants using significant unobservable inputs (level 3) The following table presents the changes in level 3 instruments for the years ended December 31, 2021, 2022 and 2023: Warrants in USD thousands Balance as of January 1, 2021 10,218 Changes during 2021: Exercises (10,295 ) Changes in fair value through profit and loss 1,936 Balance as of December 31, 2021 1,859 Changes during 2022: Issuances 9,075 Changes in fair value through profit and loss (6,425 ) Balance as of December 31, 2022 4,509 Changes during 2023: Exercises (3,631 ) Changes in fair value through profit and loss 11,054 Balance as of December 31, 2023 11,932

CRITICAL ACCOUNTING ESTIMATES A

CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS	12 Months Ended
	Dec. 31, 2023
Disclosure Of Accounting Judgements And Estimates Explanatory Abstract
CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS	NOTE 4 – CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS As part of the financial reporting process, Company management is required to make estimates that affect the value of assets, liabilities, income, expenses and certain disclosures included in the Company’s consolidated financial statements. By their very nature, such accounting estimates are subjective and complex and consequently may differ from actual results. The estimates are continually evaluated and adjusted based on historical experience and other factors, including expectation of future events that are believed to be reasonable under the circumstances. Below are the critical accounting estimates used in the preparation of the financial statements that required Company management to make assumptions involving significant uncertainty. Impairment of indefinite-lived intangible assets As mentioned in Notes 2f and 2g, the Company performs impairment reviews of intangible assets not subject to amortization on an annual basis, or more frequently if events or changes in circumstances indicate a potential impairment. The recoverable amount is determined using discounted cash flow calculations. The analysis estimates the future cash flows the Company expects to derive from the asset, incorporates expectations about possible variations in the amount or timing of those future cash flows, as well as the uncertainty inherent in the asset, and the risk-adjusted cash flows are then discounted using the Company’s estimated post-tax weighted average cost of capital (“WACC”). The main estimates used in calculating the recoverable amount include the WACC estimation and the amounts and timing of projected future cash flows. Such amounts and timing are influenced by the expected outcome of development activities, the probability of success and timing in gaining regulatory approval, size of the potential market and the Company’s specific market share, either via direct sales or a potential out-licensing deal. In light of the Company’s decision to terminate AGI-134, the value of its intangible asset was written off in its entirety. Following the approval and subsequent launch of motixafortide towards the end of 2023, the Company began to amortize the intangible asset related to motixafortide concurrently with related recognition of revenue (see Note 16). Fair value estimations of warrants As described in Notes 3d and 12c, the Company completed financing transactions in which it issued ADSs and warrants to purchase additional ADSs. The fair value of the warrants, which are not traded on an active market, is determined by using valuation techniques. These valuation techniques maximize the use of observable market data where it is available and rely as little as possible on entity specific estimates. License revenue recognition In determining the amounts to be recognized as revenue relating to the out-licensing transaction with HST and Gloria, the Company was required to use significant judgement in the following matters: • The allocation of consideration between the license agreement and the SPA, based on the fair value of the Company’s shares on the date considered as the closing date of the transaction • The estimated stand-alone, selling-price value between the contract components (i.e., between the main therapeutic areas covered by the contract), as well as the performance obligations relating to each of the components • The period of time over which revenue should be recognized for each component. The revenue recognition method is the ratio of support hours to the total hours expected to be incurred. Recognition and measurement of allowance for rebates, chargebacks and returns The Company makes several key estimations related to gross-to-net (GTN) revenue, which are recognized as revenue reductions and for which unsettled amounts are accrued. The primary measures calculated include rebates, Medicaid and other governmental rebates, chargebacks, and returns. The allowance is calculated based on common practices in the industry and the estimated utilization of rebate and chargeback programs at the time revenue is recognized. The main estimates used in recognizing and measuring this allowance relate to the volume of products sold to distributors but not yet prescribed to patients. The Company periodically evaluates its estimates against actual results and updates them accordingly as necessary.

CASH AND CASH EQUIVALENTS

CASH AND CASH EQUIVALENTS	12 Months Ended
	Dec. 31, 2023
Cash and cash equivalents [abstract]
CASH AND CASH EQUIVALENTS	NOTE 5 – CASH AND CASH EQUIVALENTS December 31, 2022 2023 in USD thousands Cash on hand and in bank 3,623 3,154 Short-term bank deposits 6,964 1,101 10,587 4,255 The short-term bank deposits included in cash and cash equivalents bear interest at annual rates of between 0.15% and 4.55%.

SHORT-TERM BANK DEPOSITS

SHORT-TERM BANK DEPOSITS	12 Months Ended
	Dec. 31, 2023
Disclosure Of Short Term Bank Deposits Abstract
SHORT-TERM BANK DEPOSITS	NOTE 6 – SHORT-TERM BANK DEPOSITS The short-term bank deposits are primarily in dollars and bear interest at annual rates of between 0.57% and 6.63%.

INVENTORY

INVENTORY	12 Months Ended
	Dec. 31, 2023
Classes of current inventories [abstract]
INVENTORY	NOTE 7 – INVENTORY December 31, 2022 2023 in USD thousands Raw materials - 903 Work-in-progress - 471 Finished goods - 579 - 1,953

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2023
Disclosure of detailed information about property, plant and equipment [abstract]
PROPERTY AND EQUIPMENT	NOTE 8 – PROPERTY AND EQUIPMENT Set forth below are the composition of property and equipment and the related accumulated depreciation, grouped by major classifications: Cost Accumulated depreciation Balance at Additions Deletions Balance at Balance at Additions Deletions Balance at Net book value beginning during during end of beginning during during end of December 31, of year year year year of year year year year 2022 2023 in USD thousands in USD thousands in USD thousands Composition in 2023 Office furniture and equipment 244 8 - 252 138 27 - 165 106 87 Computers and communications equipment 961 101 - 1,062 712 108 - 820 249 242 Laboratory equipment 1,606 7 - 1,613 1,578 20 - 1,598 28 15 Leasehold improvements 2,036 - - 2,036 1,693 214 - 1,907 343 129 4,847 116 - 4,963 4,121 369 - 4,490 726 473

INTANGIBLE ASSETS

INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2023
Disclosure of detailed information about intangible assets [abstract]
INTANGIBLE ASSETS	NOTE 9 – INTANGIBLE ASSETS Intellectual property included the following intangible assets acquired by the Company: - $6.7 million recorded as a result of the acquisition of Agalimmune, primarily related to its main drug candidate, AGI-134 (see Note 1a). , the Company made a decision to terminate the development of AGI-134. Accordingly, the intellectual property related to AGI-134 has been written-off in the 2023 financial statements. - $15.0 million associated with BL-8040 were recorded following an amendment to the in-licensing agreement with Biokine Therapeutics Ltd. ("Biokine"). This amendment reduced the payments owed by the Company on sublicense receipts (as defined in the license agreement) from 40% to 20%. This intellectual property is amortized proportionally with the revenues recognized from the licensing transaction with HST and Gloria in Asia (see Note 16), as well as in accordance with the lifespan of the patents in the U.S., following commencement of self-commercialization of motixafortide towards the end of 2023. Set forth below are the composition of intangible assets and the related accumulated depreciation, grouped by major classifications: Cost Accumulated depreciation and impairment Balance at Additions Disposal Balance at Balance at Additions Impairment Balance at Net book value beginning during during end of beginning during during end of December 31, of year year year year of year year year year 2022 2023 in USD thousands in USD thousands in USD thousands Composition in 2023 Intellectual property 21,792 - 450 21,342 96 - 6,703 6,799 21,696 14,543 Computer software 801 181 - 982 612 59 - 671 189 311 22,593 181 450 22,324 708 59 6,703 7,470 21,885 14,854

LEASES

LEASES	12 Months Ended
	Dec. 31, 2023
Presentation of leases for lessee [abstract]
LEASES	NOTE 10 – LEASES A. Right-of-use assets Cost Accumulated depreciation Balance at Additions Deletions Balance at Balance at Additions Deletions Balance at Net book value beginning during during end of beginning during during end of December 31, of year year year year of year year year year 2022 2023 in USD thousands in USD thousands in USD thousands Composition in 2023 Property 2,097 - - 2,097 582 388 - 970 1,515 1,127 Motor vehicles 336 149 117 368 79 118 117 80 257 288 2,433 149 117 2,465 661 506 117 1,050 1,772 1,415 B. Lease liabilities Balance at Additions Deletions Interest expense Exchange differences Payments Balance at beginning during during during during during end of of year year year year year year year in USD thousands Composition in 2023 Property 1,920 - - 236 (38 ) (562 ) 1,556 Motor vehicles 236 149 - 37 (4 ) (156 ) 262 2,156 149 - 273 (42 ) (718 ) 1,818 C. Additional disclosures 1) The Company leases two premises – its corporate headquarters and development facilities in Modi’in, Israel, and its U.S. commercial headquarters in Waltham, Massachusetts. a. The Company leases its premises in Israel under a lease agreement entered into in August 2014. Payments under the lease commenced in June 2015, and the initial term of the lease expired in June 2020. The Company exercised its option to extend the lease through June 30, 2025, and has the option to extend the lease for two additional lease periods totaling up to five additional years, each option at a 5% increase to the preceding lease payment amount. The monthly lease payment is approximately $25,000. In addition, the Company pays building maintenance charges of approximately $8,000 per month. b. The Company leases its premises in Boston under a lease agreement entered into and commenced in October 2022. The term of the lease will expire in December 2024. The monthly lease fee is approximately $24,000. 2) The Company has entered into lease agreements in connection with a number of vehicles. The lease periods are generally for three years. The annual lease fees, linked to the CPI, are approximately $303,000. To secure the terms of the lease agreements, the Company has prepaid two months of lease payments to the leasing companies. 3) As of December 31, 2023, minimum future rental payments (taking into consideration the aforementioned extension periods) under the leases are as follows: Year Property Motor vehicles Total in USD thousands 2024 575 161 736 2025 292 113 405 2026 292 26 317 2027 306 - 306 2028-2030 766 - 766 2,231 300 2,531 Extension and termination options are included in most of the property leases. These are used to maximize operational flexibility in terms of managing the assets used in the Company’s operations. The substantial majority of extension and termination options are exercisable solely by the Company and not by the lessors.

LONG-TERM LOANS

LONG-TERM LOANS	12 Months Ended
	Dec. 31, 2023
Disclosure of detailed information about borrowings [abstract]
LONG-TERM LOANS	NOTE 11 – LONG-TERM LOANS In October 2018, the Company entered into a $10 million loan agreement with Kreos Capital. This loan was repaid in full in September 2022. In September 2022, the Company entered into a new $40 million loan agreement with Kreos Capital (via Kreos Capital VII Aggregator SCSp). Pursuant to the new agreement, the first tranche of $10 million was drawn down by the Company upon closing. The remaining $30 million will be made available in two additional tranches subject to the achievement of pre-specified milestones. The tranches are available for drawdown at the Company’s discretion at various time points through October 1, 2024. Each tranche carries a pre-defined interest-only payment period, followed by a loan principal amortization period of up to 36 months subsequent to the interest-only period. The interest-only periods are subject to possible extension based on certain pre-defined milestones. Borrowings under the financing bear interest at a fixed annual rate of 9.5% (~11.0%, including associated cash fees). As security for the loan, Kreos Capital received a first-priority secured interest in all Company assets, including intellectual property, and the Company undertook to maintain a minimum cash balance. In addition, Kreos Capital is entitled to mid-to-high single-digit royalties on motixafortide sales in the U.S., up to a pre-defined cap. The loan's current value includes the accrual of effective interest, including estimated future royalties.

EQUITY

EQUITY	12 Months Ended
	Dec. 31, 2023
Disclosure of classes of share capital [abstract]
EQUITY	NOTE 12 – EQUITY a. Share capital The Compan y’s share capital is composed of ordinary shares, as follows: Number of Ordinary Shares December 31, 2022 2023 Authorized share capital 2,500,000,000 2,500,000,000 Issued and paid-up share capital 922,958,942 1,086,589,165 In USD and NIS Amounts December 31, 2022 2023 Authorized share capital (in NIS) 250,000,000 250,000,000 Issued and paid-up share capital (in NIS) 92,295,894 108,658,916 Issued and paid-up share capital (in USD) 27,100,201 31,355,056 b. Rights related to shares The ordinary shares confer upon their holders voting and dividend rights and the right to receive assets of the Company upon its liquidation. As of December 31, 2022 and 2023, all outstanding share capital consisted of ordinary shares. c. Changes in the Company’s equity 1) In connection with the loan agreement with Kreos Capital signed in October 2018 (see Note 10), Kreos Capital received warrants to purchase 63,837 ADSs at an exercise price of $14.10 per ADS. The warrants issued have been classified as a financial liability due to a net settlement provision. The warrant is exercisable for a period of ten years from the date of issuance. The fair value of the warrants at the date of issuance, computed using the Black-Scholes option pricing model, amounted to $861,000. The fair value of the warrants was immaterial as of December 31, 2023 (December 31, 2022 – also immaterial), and was based on the then current price of an ADS, a risk-free interest rate of 3.84%, an average standard deviation of 84.7%, and on the remaining contractual life of the warrants. The change in fair value for the years ended December 31, 2022 and 2023, of $36,000 and $21,000, respectively, has been recorded as non-operating income on the statement of comprehensive loss. As of December 31, 2023, none of these warrants had been exercised. 2) In February 2019, the Company completed an underwritten public offering of 1,866,667 of its ADSs and warrants to purchase 1,866,667 ADSs, at a public offering price of $8.25 per ADS and accompanying warrant. The warrants were exercisable immediately, were to expire five years from the date of issuance and had an exercise price of $11.25 per ADS. The offering raised a total of $15.4 million, with net proceeds of $14.1 million, after deducting fees and expenses. The amount of the offering consideration initially allocated to the warrants was $5.0 million. Total issuance costs initially allocated to the warrants were $0.4 million. The warrants have been classified as a financial liability due to a net settlement provision. This liability was initially recognized at its fair value on the date the contract was entered into and is subsequently accounted for at fair value at each balance sheet date. The fair value changes are charged to non-operating income and expense in the statement of comprehensive loss. The fair value of the warrants as of December 31, 2023 was immaterial (December 31, 2022 – also immaterial). The change in fair value for the year ended December 31, 2022 of $563,000 was recorded as non-operating income on the statement of comprehensive loss. The change in fair value for 2023 was immaterial. As of December 31, 2023, none of these warrants had been exercised, and they expired in February 2024. 3) In May and June 2020, the Company sold in registered direct offerings an aggregate of 7,653,145 ADSs at a price of $1.75 per ADS. The Company also issued to investors in the offerings unregistered warrants to purchase 7,653,145 ADSs. The warrants were exercisable immediately, were to expire two and half years from the date of issuance and had an exercise price of $2.25 per ADS. In addition, the Company granted to the placement agent’s designees, as part of the placement fees, warrants to purchase 382,657 ADSs. These warrants were exercisable immediately, were set to expire two and half years from the date of issuance and had an exercise price of $2.1875 per ADS. The offerings raised a total of $13.4 million, with net proceeds of $12.0 million, after deducting fees and expenses. The amount of the offering consideration initially allocated to the warrants was $5.7 million. Total issuance costs initially allocated to the warrants were $0.6 million. The warrants issued were classified as a financial liability due to a net settlement provision. This liability was initially recognized at its fair value on the date the contract was entered into and is subsequently accounted for at fair value at each balance sheet date. The fair value changes were charged to non-operating income and expense in the statement of comprehensive loss. Prior to their expiration in November 2022, 5,739,741 of these warrants were exercised. The change in fair value for the year ended December 31, 2022 of $1,253,000 was recorded as non-operating income on the statement of comprehensive loss. 4) In January 2021, the Company completed an underwritten public offering of 14,375,000 of its ADSs at a public offering price of $2.40 per ADS. The offering raised total gross proceeds of $34.5 million, with net proceeds of $31.4 million after deducting fees and expenses. In addition, warrants to purchase 718,750 ADSs were granted to the underwriters. These warrants are exercisable immediately, expire five years from the date of issuance and have an exercise price of $3.00 per ADS. The warrants have been classified as shareholders’ equity, with initial recognition at fair value on the date issued. The total issuance costs initially allocated to the warrants were recorded as an offset to share premium. The fair value of the warrants on the issuance date was approximately $1.0 million, which was recorded as issuance costs, and computed using the Black and Scholes option pricing model, based upon the then current price of an ADS, a risk-free interest rate of approximately 0.45% and an average standard deviation of approximately 73.8%. As of December 31, 2023, none of these warrants had been exercised. 5) In September 2022, the Company completed a registered direct offering of 13,636,365 ADSs at a price of $1.10 per ADS. The Company also issued to investors in the offering unregistered warrants to purchase 13,636,365 ADSs. The warrants are exercisable immediately, expire five years from the date of issuance and have an exercise price of $1.15 per ADS. In addition, the Company granted to the placement agent in the offering, as part of the placement fee, warrants to purchase 681,818 ADSs. These warrants are exercisable immediately, expire five years from the date of issuance and have an exercise price of $1.375 per ADS. Gross proceeds from the offering totaled $15.0 million, with net proceeds of $13.5 million, after deducting fees and expenses. The offering consideration allocated to the placement agent warrants amounted to $0.4 million. The warrants issued to the investors have been classified as a financial liability due to a net settlement provision. This liability was initially recognized at its fair value on the issuance date and is subsequently accounted for at fair value at each balance sheet date. The fair value changes are charged to non-operating income and expense in the statement of comprehensive loss. The fair value of the warrants is computed using the Black-Scholes option pricing model. The fair value of the warrants upon issuance was computed based on the then-current price of an ADS, a risk-free interest rate of 3.62%, and an average standard deviation of 82.5%. The gross consideration initially allocated to the investor warrants amounted to $9.1 million, with total issuance costs initially allocated to the warrants amounting to $0.8 million. The fair value of the warrants amounted to $11,905,000 as of December 31, 2023 (December 31, 2022 - $4,502,000), and was based on the then current price of an ADS, a risk-free interest rate of 3.9%, an average standard deviation of 86.5%, and on the remaining contractual life of the warrants. The changes in fair value for the years ended December 31, 2022 and 2023 of $4,573,000 and $11,033,000, respectively, have been recorded as non-operating income (expenses) in the statement of comprehensive loss. As of December 31, 2023, 2,545,455 of these warrants had been exercised. The placement agent warrants have been classified in shareholders’ equity, with initial recognition at fair value on the date issued, using the same assumptions as the investor warrants. 6) On August 27, 2023, the Company entered into a securities purchase agreement, pursuant to which the Company agreed to sell in a private placement an aggregate of 6,829,137 ADSs of the Company, at a purchase price of $2.136 per ADS. Aggregate gross proceeds from the sale, which were received by the Company at closing, amounted to $14.6 million, with related issuance costs amounting to approximately $0.9 million. Pursuant to IFRS 15, approximately $12.0 million of gross proceeds and $0.7 million of issuance costs were recognized as equity. (see Note 16). d. Share purchase agreements 1) In September 2020, the Company entered into an ATM sales agreement with H.C. Wainwright & Co., LLC (“HCW”), pursuant to which the Company was entitled, at its sole discretion, to offer and sell through HCW, acting as sales agent, ADSs having an aggregate offering price of up to $25.0 million throughout the period during which the ATM facility remained in effect. The Company agreed to pay HCW a commission of 3.0% of the gross proceeds from the sale of ADSs under the facility. Expenses associated with establishment of the ATM facility with HCW, amounting to $0.2 million, were recorded in 2020 as non-operating expenses. In September 2021, the Company terminated the agreement. During 2021, the Company issued a total of 4,745,368 ADSs under the agreement for total gross proceeds of $18.5 million. From the effective date of the agreement through its termination, 7,381,101 ADSs were sold under the program for total gross proceeds of approximately $24.5 million. 2) In September 2021, the Company entered into a new $25.0 million ATM sales agreement with HCW under substantially identical terms to the previous agreement. Expenses associated with establishment of the ATM facility with HCW, amounting to $0.1 million, were recorded in non-operating expenses during the period. During 2023, the Company issued a total of 1,501,207 ADSs under the program for total gross proceeds of approximately $2.9 million. From the effective date of the agreement through the issuance date of this report, 2,109,858 ADSs have been sold under the program for total gross proceeds of approximately $4.4 million and a total fees of approximately $0.1 million. e. Share-based payments 1) Share Incentive plan – general In 2003, the Company adopted the 2003 Share Incentive Plan (the “Plan”). The Plan provides for the granting of stock options and ordinary shares to the Company’s employees, directors, consultants and other service providers. Options are issued at the determination of the Board of Directors in accordance with applicable law. The options are generally exercisable for a ten-year period and the grants generally vest over a four-year period. In 2013, the Company’s Board of Directors approved amendments to the Plan to take into account changes in laws and regulations that had occurred since its adoption and to extend the term of the plan until November 2023. In 2016, the Board of Directors approved amendments to the Plan to allow for the grant of restricted stock units (“RSUs”) and performance stock units (“PSUs”). In 2022, the Board approved certain amendments to the Plan in order to conform the Plan to U.S. tax regulations for the benefit BioLineRx USA, Inc. employees. In November 2023, the Company’s Board of Directors approved to extend the term of the plan until May 2024. PSUs are RSUs that are linked to any one or more performance goals (in addition to, or in lieu of, time-based vesting terms) determined appropriate by the Board of Directors. The specific performance goals, as well as the time period associated with achieving such goals, are approved by the Board and are set forth in the grantee’s grant agreement. To date, each PSU grant has had between three to five performance goals on which vesting is based, each such goal being either a specified Company milestone and or the success of a specific project, with vesting of 20-40% on the achievement of each goal. The tranche of PSUs associated with a given milestone expires 12 months after the target date established for that milestone. As of December 31, 2023, 8,336,970 PSUs were vested in accordance with their original terms. 1) Share Incentive plan – general (cont.) As of December 31, 2023, there were 153,154,860 ordinary shares issuable upon the exercise of outstanding equity instruments under the Plan. Company Israelis’ employees and directors are granted options under Section 102 of the Israeli Income Tax Ordinance (the “Ordinance”), primarily under the “capital gains” track. Israeli non-employees of the Company (consultants and other service providers) are granted options under Section 3(i) of the Ordinance. All non-Israeli employees and non-employees of the Company are granted options as non-qualifies. As of December 31, 2023, there were 17.7 million remaining authorized but unissued ordinary shares in the pool reserved for future share-based incentive grants. 2) Employee share incentive plan: The following table contains additional information concerning equity instruments granted to employees and directors under the existing share incentive plans. Year ended December 31, 2021 2022 2023 Number of options Weighted average exercise price (in NIS) Number of options Weighted average exercise price (in NIS) Number of options Weighted average exercise price (in NIS) Outstanding at beginning of year 35,981,579 1.5 40,956,214 0.7 89,871,858 0.4 Granted 6,588,200 0.4 53,696,305 0.3 64,855,380 0.2 Forfeited and expired (1,438,642 ) 3.0 (4,618,062 ) 0.8 (3,804,175 ) 0.7 Exercised (174,923 ) 0.1 (162,599 ) 0.1 (493,238) 0.2 Outstanding at end of year* 40,956,214 0.7 89,871,858 0.4 150,429,825 0.3 Exercisable at end of year 18,663,353 1.7 26,663,961 0.8 51,970,635 0.5 * As of December 31, 2021, 2022 and 2023, includes 4,084,748, 10,482,277, and 12,219,465 PSUs at an exercise price of 0.10 NIS (par value of ordinary shares), for which performance obligations have not been met. The total consideration received from the exercise of equity instruments during 2021, 2022 and 2023 was not material. Set forth below is data regarding the range of exercise prices and weighted-average remaining contractual life (in years) for the equity instruments outstanding at the end of each of the years indicated. As of December 31, 2022 2023 Range of exercise prices (in NIS) Number of options outstanding Weighted average remaining contractual life (in yrs.) Number of options outstanding Weighted average remaining contractual life (in yrs.) Up to 0.49 58,488,372 9.2 120,593,415 8.8 0.5-0.99 17,175,120 7.8 16,147,110 6.9 1.00-2.00 13,668,366 5.5 13,149,390 4.7 2.01-3.4 540,000 4.2 539,910 3.2 89,871,858 8.4 150,429,825 8.2 The fair value of equity instruments granted to employees through December 31, 2023 has been determined using the Black-Scholes option-pricing model. These values are based on the following assumptions as of the applicable grant dates: 2021 2022 2023 Expected dividend yield 0 % 0 % 0 % Expected volatility 67 % 67 % 69 % Risk-free interest rate 1 % 4 % 4 % Expected life of options (in years) 6 6 6 The remaining unrecognized deferred compensation expense as of December 31, 2023 was $2.7 million. This amount will be expensed over the remaining vesting period of the equity instruments. 3) Stock options to consultants From inception through December 31, 2021, the Company issued to consultants options for the purchase of 3,296,523 ordinary shares at a weighted average exercise price of NIS 5.23 per share. In 2022 and 2023, the Company did not issue additional options to consultants. The options to consultants generally vest over four years and may be exercised for periods of between five and ten years. As of December 31, 2023, 2,725,035 options to consultants were outstanding with a weighted average exercise price of NIS 1.01 per share and a weighted average contractual life of 6.9 years. Company management estimates the fair value of the options granted to consultants based on the value of services received over the vesting period of the applicable options. The value of such services (primarily in respect of clinical advisory services) is estimated based on the additional cash compensation the Company would need to pay if such options were not granted. The value of services recorded in each of the years 2021, 2022 and 2023 was not material.

TAXES ON INCOME

TAXES ON INCOME	12 Months Ended
	Dec. 31, 2023
Disclosure Of Income Taxes [Abstract]
TAXES ON INCOME	NOTE 13 – TAXES ON INCOME a. Corporate taxation The taxable income of BioLineRx Ltd., not subject to benefits as detailed below, is taxed at the standard Israeli corporate tax rate, which was 23% for all years included in these financial statements. The taxable income of BioLineRx USA, Inc. is subject to a federal tax rate of 21%. b. Tax loss carryforwards As of December 31, 2023, the tax loss carryforwards of BioLineRx Ltd. were approximately $304 million. The tax loss carryforwards have no expiration date. c. Tax assessments In accordance with Israeli tax regulations, the tax returns filed by BioLineRx Ltd. through the 2020 tax year are considered final. d. Theoretical taxes The Company has not recognized any deferred tax assets in the financial statements, as it does not expect to generate taxable income in the foreseeable future. The reported tax on the Company’s income before taxes differs from the theoretical amount that would arise using the weighted average tax rate applicable to income of the consolidated entities as follows: Year ended December 31, 2021 2022 2023 in USD in USD in USD thousands thousands thousands Loss before taxes 23.0 % (27,045 ) 23.0 % (24,951 ) 23.0 % (60,614 ) Theoretical tax benefit (6,220 ) (5,739 ) (13,941 ) Disallowed deductions (tax exempt income): Loss (gain) on adjustment of warrants to fair value 480 (1,478 ) 2,542 Share-based compensation 343 516 534 Impairment of intangible asset - - 1,542 Other 11 11 11 Increase in taxes for tax losses and timing differences incurred in the reporting year for which deferred taxes were not created 5,386 6,690 9,312 Taxes on income for the reported year - - -

LOSS PER SHARE

LOSS PER SHARE	12 Months Ended
	Dec. 31, 2023
Earnings per share [abstract]
LOSS PER SHARE	NOTE 14 – LOSS PER SHARE The following table contains the data used in the computation of the basic loss per share: Year ended December 31, 2021 2022 2023 in USD thousands Loss attributed to ordinary shares (27,054 ) (24,951 ) (60,614 ) in thousands Number of shares used in basic calculation 662,934 773,957 963,366 in USD Basic and diluted loss per ordinary share (0.04 ) (0.03 ) (0.06 ) All outstanding options and warrants have been excluded from the calculation of the diluted loss per share for all years presented, since their effect was anti-dilutive.

COMMITMENTS AND CONTINGENT LIAB

COMMITMENTS AND CONTINGENT LIABILITIES	12 Months Ended
	Dec. 31, 2023
Disclosure of commitments and contingent liabilities [Abstract]
COMMITMENTS AND CONTINGENT LIABILITIES	NOTE 15 – COMMITMENTS AND CONTINGENT LIABILITIES a. Commitments 1) Obligation to pay royalties to the State of Israel The Company is required to pay royalties to the State of Israel (represented by the Israel Innovation Authority, or IIA), computed on the basis of proceeds from the sale or license of products whose development was supported by grants from the predecessor of the IIA, the Office of the Chief Scientist. This obligation relates solely to financial participation in the development of products by the Company. In accordance with the terms of grants provided by the IIA, the State is entitled to royalties on the sale or license of any product whose development was supported with State participation. These royalties are generally 3% in the first three years from initial repayment, 4% of sales in the three subsequent years and 5% of sales in the seventh year until repayment of 100% of the grants (linked to the dollar) received by the Company, plus annual interest at the LIBOR rate. Starting January 2024, the interest rate will be the 12-month SOFR rate as published on the first trading day of each calendar year. Under certain circumstances, the royalty rate is calculated according to a formula based on the ratio of participation by the IIA in the project to the total project costs incurred by the Company. 2) In connection with the in-licensing of motixafortide from Biokine Therapeutics Ltd. (“Biokine”), and as a condition to IIA consent to the transaction, the Company agreed to abide by any obligations resulting from funds previously received by Biokine from the IIA. The contingent liability to the IIA assumed by the Company relating to this transaction amounts to $3.2 million as of December 31, 2023. In this regard, and in connection with the outlicensing transaction in Asia (see Note 16), as well as the commercial launch of motixafortide in the U.S., the royalty rate agreed with the IIA for motixafortide consideration received is 3.9% for sub-license consideration and 4% for direct product sales. The Company has a full right of offset for amounts payable to the IIA from all payments due to Biokine in the future. 3) Licensing agreements From time to time, the Company enters into in-licensing agreements with academic institutions, research institutions and companies (the “licensors”) in connection with the development of therapeutic compounds. Pursuant to these licensing agreements, the Company generally obtains the rights for one or more therapeutic compounds in pre-clinical and early clinical stages of development, in order to continue development of the compounds through more advanced stages of development and, subsequently, to manufacture, distribute and market the drugs or to out-license the development, manufacturing and commercialization rights to third parties. Such development activities are carried out by either the Company and/or by companies or institutions to which the Company has entered into an out-license agreement, subject to certain restrictions stipulated in the various agreements. The licenses that have been granted to the Company are broad and comprehensive, and generally include various provisions and usage rights as follows: (i) territorial scope of the license (global); (ii) term of the license (unrestricted but not shorter than the life of the patent); and (iii) development of the therapeutic compound (allowing the Company to perform all development activities on its own, or by outsourcing under Company supervision, as well as out-licensing development under the license to other companies, subject to the provisions of the licensing agreements). According to the provisions of the licensing agreements, the intellectual property rights in the development of any licensed technology, through the date the applicable license agreement is effective, remain with the licensor, while the rights in products and/or other deliverables developed by the Company after the license is granted belong to the Company. In cases where the licensor has a claim to an invention that was jointly developed with the Company, the licensor also co-owns the related intellectual property. In any event, the scope of the license also covers these intellectual property rights. In addition, the Company generally undertakes in the licensing agreements to protect registered patents resulting from developments under the various licenses, to promote the registration of patents covering new developments in cooperation with the licensor, and to bear responsibility for all related costs. Pursuant to the various agreements, the Company generally works to register the various patents on a broad basis worldwide, and if the Company decides not to initiate or continue a patent registration proceeding in a given country, the Company is required to notify the applicable licensor to this effect and the licensor is entitled to take action for registration of the patent in such country. The consideration paid pursuant to the licensing agreements generally includes several components that may be payable over the license period and that relate, inter alia, to the progress made in research and development activities, as well as commercial success, as follows: (a) one-time, up-front payment and/or periodic payments; (b) payments through the early stages of development (i.e., through the end of phase 2); (c) payments upon the achievement of milestones necessary for advancing to phase 3; (d) payments from the end of a successful phase 3 trial through approval of the therapeutic compound; and e) royalties on sales of the final product resulting from development under the license or including any component thereof, generally less than 5% of the Company’s net sales of the product, although in specific instances (for example, with regard to motixafortide, where the royalty rate on net sales directly commercialized by the Company payable to Biokine is 10%) the royalty rate has been higher or lower than this range. In instances where the Company has out-licensed the product for further development, the Company pays a percentage of the net consideration received from the licensee (“Sublicense Receipts”) to the upstream licensor that generally range from 20% to 29.5% of such consideration, although in specific instances the percentage paid has been higher or lower than this range. These Sublicense Receipts generally take the place of most or all of the milestone and royalty payments set forth in (b) through (e) above. The license agreements may be cancelled by the licensor only in specific circumstances, generally upon the occurrence of one of the following events: (a) the Company’s failure to meet certain milestones stipulated in the applicable license agreement and appended timetables; (b) default, insolvency, receivership, liquidation, etc. of the Company that is not imposed and/or lifted within the timeframe stipulated in the license agreement; and (c) fundamental breach of the license agreement that is not corrected within the stipulated timeframe. The Company may generally cancel a license agreement with prior notice of 30 to 90 days, due to unsuccessful development or any other cause. The Company has undertaken to indemnify certain licensors, their employees, officers, representatives or anyone acting on their behalf for any damage and/or expense that they may incur in connection with the Company’s use of a license granted to it, all in accordance with the terms stipulated in the applicable license agreements. Some of the license agreements are accompanied by consulting, support and cooperation agreements, pursuant to which the Company is committed to pay the various licensers a fixed monthly amount over the period stipulated in the agreement for their assistance in the continued research and development under the license. 4) Commitments in respect of Agalimmune and Biokine The consideration due to Agalimmune shareholders is based on certain development and commercial milestones, including future sales of Agalimmune products. In addition, the selling shareholders of Agalimmune have certain reversionary rights in the event of a breach of the transaction agreement and certain other limited triggering events. In December 2023, the Company determined to terminate development of AGI-134 and provided notice of its intent to terminate the Agalimmune Development Agreement, effective March 15, 2024. The Company is currently awaiting the decision of Agalimmune’s founders regarding their intent to exercise their reversionary option right. In accordance with the license agreement of motixafortide with Biokine (as amended), the Company is required to pay Biokine a payment of 20% of amounts received as consideration in connection with any sublicensing or sale of the licensed technology. Biokine is also eligible to receive up to a total of $2.5 million in future milestone payments. Subject to certain limitations, if the Company independently sells products related to motixafortide, the Company will pay Biokine a royalty payment of 10% of net sales. 5) Purchase orders The Company’s outstanding open purchase order commitments as of December 31, 2023 amounted to $6.9 million. b. Guarantees To secure the Company’s lease obligation on its Israeli premises, the Company has provided a bank guarantee in the amount of $100,000 for the benefit of the lessor, which remains outstanding as of December 31, 2023. c. Contingent liabilities On January 5, 2023, a putative securities class action complaint was filed in the U.S. against the Company and its Chief Executive Officer. The complaint claims that the Company made false and materially misleading statements and failed to disclose material adverse facts pertaining to its financial position with regard to the development of motixafortide and that the Company would require a loan and a securities offering to commercialize motixafortide. The complaint asserts a putative class period of February 23, 2021 to September 19, 2022, inclusive, and seeks certification as a class action and an unspecified amount of damages. On July 5, 2023, an amended complaint was filed, alleging the same claims and adding the Company’s Chief Financial Officer. On September 5, 2023, the Company, its Chief Executive Officer and its Chief Financial Officer filed a motion to dismiss the amended complaint in its entirety. The motion has been fully briefed and is sub judice. The Company also received, on February 5, 2023, a substantially similar lawsuit and motion to approve the lawsuit as a class action in the Tel Aviv District Court. The total amount claimed in Tel Aviv, if the lawsuit is certified as a class action, is approximately NIS 113.5 million (approximately $32 million). The outcome of both legal proceedings is uncertain at this point. Based on an initial evaluation, management of the Company believes they are without merit and intends to vigorously defend against such actions.

LICENSE AND SECURITIES PURCHASE

LICENSE AND SECURITIES PURCHASE AGREEMENTS	12 Months Ended
	Dec. 31, 2023
License And Securities Purchase Agreements [Abstract]
LICENSE AND SECURITIES PURCHASE AGREEMENTS	NOTE 16 – LICENSE AND SECURITIES PURCHASE AGREEMENTS On August 27, 2023, the Company entered into a license agreement (the “License Agreement”) with Hong Seng Technology Limited (“HST”) and Guangzhou Gloria Biosciences Co., Ltd. (“Gloria” and together with HST, the “Purchaser Parties” or the “Licensee”), pursuant to which the Company granted HST an exclusive, royalty-bearing, sublicensable license to develop and commercialize motixafortide in Asia (other than Israel and certain other countries) (collectively, the “Territory”) and to engage and authorize Gloria to perform services under the License Agreement in the Territory. In addition, the Company granted the Licensee a first offer right with respect to the grant of certain rights in motixafortide outside of the Territory. The License Agreement became effective on October 12, 2023, following fulfillment of all closing conditions. Pursuant to the terms of the License Agreement, the Licensee paid an upfront payment of $15 million, which was received by the Company at closing. The Company is also entitled to up to $49 million based on the achievement of certain development and regulatory milestones in China and Japan, and up to $197 million in sales milestones based on defined sales targets of motixafortide in the Territory. In addition, the Company is eligible to receive tiered double-digit royalties (ranging from 10-20%), on a country-by-country basis, on aggregate net sales of motixafortide in the Territory during the initial royalty term of at least 15 years, with a reduction of the royalties payable following the end of the initial royalty term, as well as upon the occurrence of certain events. In connection with the License Agreement, on August 27, 2023, the Company also entered into a securities purchase agreement (the “Purchase Agreement”) with HST and Gloria, pursuant to which the Company agreed to sell in a private placement an aggregate of 6,829,137 ADSs of the Company, at a purchase price of $2.136 per ADS. Aggregate gross proceeds from the sale, which were received by the Company at closing, amounted to $14.6 million, with related issuance costs amounting to approximately $0.9 million. No warrants were issued in the transaction. In accordance with IFRS 15, both agreements have been treated as a single unit of account, with the consideration combined and subsequently allocated between the Purchase Agreement and the License Agreement. • TheOf the total consideration received wasamounting to $29.6 million; approximately, $12.0 million were allocated to the Purchase Agreement, and $1417.6 million were allocated to the share purchase agreement, and license agreement respectively.License Agreement • Costs in the amount of $0.7 million directly attributable to the share purchase agreementPurchase Agreement were recognized as a deduction fromreduction in equity in the amount of $0.704 million. The Company has identified the following performance obligations in the contract, each to be recognized separately: 1. SCM license 2. SCM support services 3. PDAC license and related support services With regard to PDAC, the Company determined that the license, together with the associated support services, should be combined into a single performance obligation, since the Licensee cannot benefit from the license without the associated support services. The support services are highly specialized for the licensed product in this indication. Licensing rights for other indications and related support were deemed immaterial. The fixed transaction price has been allocated among the performance obligations based on similar price offers received by the Company, with the assistance of a valuation specialist. The variable consideration related to the performance obligations was not taken into account in the fixed transaction price due to uncertainty. The variable consideration related to certain performance obligations was not taken into account in the fixed transaction price due to uncertainty. Revenue will be recognized in the Company’s financial statements as follows: a. Revenue for the SCM license was recognized in Q4 2023, upon the transfer of control over the license to the licensee, in the amount of approximately $2.0 million. b. Revenue from providing the SCM support services will be recognized using expected to result in straight-line revenue recognition over six months, totaling approximately $0.1 million. c. Revenue from the PDAC performance obligation will be recognized over time, with the percentage of completion determined based on support hours incurred, and expected to be recognized over twelve monthsthrough the end of 2024, in the total amount of $15.5 million. Costs associated directly with the license agreement have been allocated to the performance obligation above and recognized concurrently with the revenue recognition.

TRANSACTIONS AND BALANCES WITH

TRANSACTIONS AND BALANCES WITH RELATED PARTIES	12 Months Ended
	Dec. 31, 2023
Disclosure of transactions between related parties [abstract]
TRANSACTIONS AND BALANCES WITH RELATED PARTIES	NOTE 17 – TRANSACTIONS AND BALANCES WITH RELATED PARTIES Transactions with related parties Expenses: Year ended December 31, 2021 2022 2023 in USD thousands Benefits to related parties: Compensation and benefits to senior management, including benefit component of equity instrument grants 2,302 2,968 3,155 Compensation and benefits to directors, including benefit component of equity instrument grants 300 507 587 Key management compensation Key management includes directors and executive officers. The compensation paid or payable to key management for services during each of the years indicated is presented below. Year ended December 31, 2021 2022 2023 in USD thousands Salaries and other short-term employee benefits 1,883 2,298 2,425 Post-employment benefits 136 131 256 Other long-term benefits 35 35 31 Share-based compensation 548 1,011 1,030 2,602 3,475 3,742

SUPPLEMENTARY FINANCIAL STATEME

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION	12 Months Ended
	Dec. 31, 2023
Disclosure of supplementary financial statement information [Abstract]
SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION	NOTE 18 – SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION a. Other receivables December 31, 2022 2023 in USD thousands Advance payments - 480 Government institutions 687 245 Other 34 105 721 830 b. Accounts payable and accruals December 31, 2022 2023 in USD thousands 1) Trade: Accounts payable: Overseas 6,061 7,704 In Israel 905 3,165 6,966 10,869 2) Other: Payroll and related expenses 931 2,184 Accrued expenses 352 662 Accrual for vacation and recreation pay 377 419 Other 84 88 1,744 3,353 The carrying amounts of accounts payable and accruals approximate their fair value, as the effect of discounting is not material. c. Revenues Year ended December 31, 2021 2022 2023 in USD thousands License revenues (see Note 16) - - 4,610 Product sales, net - - 190 - - 4,800 d. Cost of revenues Year ended December 31, 2021 2022 2023 in USD thousands Cost related to license revenues - - 3,230 Amortization of intangible asset in respect of license revenues - - 450 Cost of product sales - - 12 - - 3,692 e. Research and development expenses Year ended December 31, 2021 2022 2023 in USD thousands Research and development services 12,088 9,296 4,603 Payroll and related expenses 4,074 4,495 4,452 Lab, occupancy and telephone 882 902 969 Professional fees 595 954 935 Share-based compensation 971 1,198 760 Depreciation and amortization 660 615 583 Other 196 169 217 19,466 17,629 12,519 f. Sales and marketing expenses Year ended December 31, 2021 2022 2023 in USD thousands Payroll and related expenses 308 947 8,868 Medical Affairs - 1,316 4,824 Marketing 700 1,805 4,091 Office related expenses - 519 1,923 Market Access - 1,023 1,606 Business Analytics - 106 1,005 Travel 25 84 986 Share-based compensation (59 ) 112 751 Professional fees - 521 745 Depreciation and amortization - - 314 Other 29 29 158 1,003 6,462 25,270 g. General and administrative expenses Year ended December 31, 2021 2022 2023 in USD thousands Payroll and related expenses 1,408 1,706 2,117 Professional fees 1,103 1,248 2,028 Insurance 1,064 1,046 939 Share-based compensation 583 895 780 Depreciation 42 39 37 Other 108 132 409 4,308 5,066 6,310 h. Non-operating income (expenses), net Year ended December 31, 2021 2022 2023 in USD thousands Changes in fair value of warrants (1,936 ) 6,425 (11,054 ) Issuance costs - (762 ) - Other 106 7 235 (1,830 ) 5,670 (10,819 ) i. Financial income Year ended December 31, 2021 2022 2023 in USD thousands Interest income 277 694 2,007 Exchange differences, net 282 - 61 559 694 2,068 j. Financial expenses Year ended December 31, 2021 2022 2023 in USD thousands Interest expense 984 1,786 2,144 Bank commissions 22 26 25 Exchange differences, net - 346 - 1,006 2,158 2,169

MATERIAL ACCOUNTING POLICIES (P

MATERIAL ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2023
Disclosure of significant accounting policies [Abstract]
Basis of presentation	a. Basis of presentation The Company’s consolidated financial statements as of December 31, 2022 and 2023, and for each of the three years in the period ended December 31, 2023, have been prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”). The material The consolidated financial statements have been prepared on the basis of historical cost, subject to adjustment of warrant liabilities to their fair value through profit or loss. The preparation of financial statements in conformity with IFRS requires management to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity and expenses, as well as the related disclosures of contingent assets and liabilities, in the process of applying the Company’s accounting policies. Actual results could differ from those estimates. Areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are material
Functional and reporting currency	b. Functional and reporting currency The functional and reporting currency in these financial statements is the U.S. dollar (“dollar”, “USD” or “$”), which is the primary currency of the economic environment in which the Company operates. Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at year-end exchange rates are generally recognized in profit or loss.
Inventory	c. Inventory Inventory is measured at the lower cost or net realizable value. The cost of inventories includes purchase costs, packaging and labeling costs, and other costs incurred in bringing the inventories to their present location and condition. Net realizable value is the estimated selling price of the inventories in the ordinary course of business, less the estimated costs necessary to make the sale. Pre-launch inventory is held as an asset when there is a high probability of regulatory approval for the product, see Note 1a. Before that point, a provision is made against the value to its recoverable amount; the provision is then reversed at the point when regulatory approval is received. Inventory is written down for estimated obsolescence based upon management assumptions about future demand, expiration due date and market conditions.
Property and equipment	d. Property and equipment Property and equipment are stated at historical cost less depreciation. Historical cost includes expenditures that are directly attributable to acquisition of the items. Assets are depreciated by the straight-line method over the estimated useful lives of the assets, provided that Company management believes the residual values of the assets to be negligible, as follows: % Computers and communications equipment 33 Office furniture and equipment 6 Laboratory equipment 15 Leasehold improvements are amortized by the straight-line method over the shorter of the lease term or the estimated useful life of the improvements.
Intangible assets	e. Intangible assets The Company applies the cost method of accounting for initial and subsequent measurements of intangible assets. Under this method of accounting, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses. Intellectual property The Company recognizes in its financial statements intellectual property developed by the Company to the extent that the conditions stipulated in paragraph o. below are met. Intellectual property acquired by the Company is initially measured at cost. Intellectual property used by the Company for development purposes and not yet generating revenues is not amortized and is tested annually for impairment. See g. below. Computer software Acquired computer software licenses are capitalized based on the costs incurred to acquire and bring to use the specific software. These costs are amortized over the estimated useful lives of the software (5 years).
Impairment of non-financial assets	f. Impairment of non-financial assets Impairment of intellectual property is required when the Company decides to terminate or suspend the development of a project based on such intellectual property. In addition, the Company performs impairment reviews on an annual basis, or more frequently if events or changes in circumstances indicate a potential impairment. Property and equipment, as well as computer software, are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized equal to the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs to sell and the asset’s value in use to the Company. See Note 9 for information about an impairment loss recorded in 2023 in connection with the decision to terminate the AGI-134 project.
Warrants	g. Warrants Receipts in respect of warrants are classified as equity to the extent that they confer the right to purchase a fixed number of shares for a fixed exercise price. In the event that the exercise price or the numbers of shares to be issued are not deemed to be fixed, the warrants are classified as a non-current derivative financial liability. This liability is initially recognized at its fair value on the date the contract is entered into and subsequently accounted for at fair value at each reporting date. The fair value changes are charged to non-operating income and expense on the statement of comprehensive loss. Issuance costs allocable to warrants classified as a liability are also recorded as non-operating expense on the statement of comprehensive loss.
Borrowings	h. Borrowings Borrowings are initially recognized at fair value, net of transaction costs incurred. Borrowings are subsequently measured at amortized cost. Any difference between the proceeds (net of transaction costs) and the redemption amount is recognized in profit or loss over the period of the borrowings using the effective interest method. With respect to long-term loans (see Note 11), a financial liability is recognized for each tranche upon drawdown. Upon initial recognition, the effective interest rate is calculated by estimating the future cash flows, including loan principal repayments, interest and royalties. The royalty feature does not meet the definition of a derivative, is not classified separately, and is not measured separately, since it is an integral part of the loan terms and conditions and cannot be transferred or settled separately from the loan. Determining the weighted effective interest rate requires certain judgments and estimations regarding the timing and amount of the Company’s future revenues. The loans are subsequently measured at amortized cost. Furthermore, revisions to the estimated amounts or timing of future cash flows, if necessary, may result in an adjustment of the amortized cost of the loan to reflect the present value of actual and revised estimated contractual cash flows, discounted using the original effective interest rate. This adjustment will be recognized in profit or loss as financial income or expense. Borrowings are classified as current liabilities unless the Company has an unconditional right to defer settlement of the liability for at least 12 months subsequent to the reporting period.
Revenues	i. Revenues The Company accounts for contract revenue in accordance with IFRS 15, “Revenue from Contracts with Customers.” IFRS 15 introduces a five-step model for recognizing revenue from contracts with customers, as follows: • identify the contract with a customer; • identify the performance obligations in the contract; • determine the transaction price; • allocate the transaction price to the performance obligations in the contract; and • recognize revenue when (or as) the entity satisfies a performance obligation. Revenues from selling products In September 2023, the FDA approved motixafortide in stem cell mobilization for autologous transplantation for multiple myeloma patients, and shortly thereafter, the Company began to independently commercialize motixafortide in the U.S. The Company sells products mainly to wholesale distributors. Gross revenues are recognized at a point in time when control over the product is transferred to the distributors (upon delivery), at the gross selling price. The net revenues reflect gross revenues, reduced by amounts attributable to distributor fees, as well as accruals of chargebacks, rebates and returns. The specific considerations the Company uses in estimating these amounts relating to variable consideration are as follows: 1. Distribution fees - The Company pays distribution fees to its three main distributors. The distribution fees are paid based on contractually determined rates from the gross consideration. When the service is received and the products sold to distributors, it is recognized as a reduction of revenues in the period the related revenues from the sale of products are recognized. 2. Rebates and patient discount programs - The Company offers various rebate and patient discount programs, which result in discounted prescriptions to qualified patients. The Company estimates the allowance for these rebates, based on the estimated utilization of the rebate and discount programs, at the time the revenues are recognized. These estimates are recognized as a reduction of revenues. 3. Product returns - The Company offers customers a right of return as part of the distributor agreements. The Company estimates the amount of product sales that may be returned by its customers and records this estimate as a reduction of revenues at the time of sale, based on estimates of product returns based on its own sales information, its visibility into the inventory remaining in the distribution channel, and product dating. Revenues from licensing agreement According to IFRS 15, performance obligations are a promise to provide a distinct good or service or a series of distinct goods or services. Goods and services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. A good or service promised to a customer is distinct if the customer can benefit from the good or service, either on its own or together with other resources that are readily available to the customer, and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. IFRS 15 defines the ‘Transaction Price’ as the amount of consideration to which the entity expects to be entitled in exchange for transferring the promised goods or services to a customer. In accordance with IFRS 15, the Company identified a number of performance obligations (components) in the contract – in respect of which revenue will be recognized separately for each component, See Note 16. The following assumptions were taken into account, as part of the revenue recognition process: 1) Development milestones: Variable payments, contingent on achieving additional milestones, are included in the transaction price based on the most likely amount method. Amounts included in the transaction price are recognized only when it is highly probable that a material 2) Sales-based royalties and sales-based milestones are recognized as the related sale occurs, due to the specific exception of IFRS 15 for sales-based royalties from licensing of intellectual properties. For more information, see Note 16.
Research and development expenses	j. Research and development expenses Research expenses are charged to profit or loss as incurred. As of December 31, 2023, the Company has not yet capitalized development expenses.
Share-based payments	k. Share-based payments The Company operates an equity-settled, share-based compensation plan, under which it grants equity instruments (options, restricted stock units and performance stock units) of the Company as additional consideration for services from employees and service providers. The fair value of the employee services received in exchange for the grant of the equity instruments is recognized as an expense. The total amount to be expensed is determined by reference to the fair value of the equity instruments granted including any market performance conditions (for example, the Company’s share price). Non-market performance and service conditions are included in assumptions about the number of equity instruments that are expected to vest. Performance stock unit expenses are recognized only if it is probable that the performance condition will be achieved.
Loss per share	l. Loss per share 1) Basic The basic loss per share is calculated by dividing the loss attributable to the holders of ordinary shares by the weighted average number of ordinary shares outstanding during the year. 2) Diluted The diluted loss per share is calculated by adjusting the weighted average number of outstanding ordinary shares, assuming conversion of all dilutive potential shares. The Company’s dilutive potential shares consist of warrants issued to investors, as well as equity instruments granted to employees and service providers. The dilutive potential shares were not taken into account in computing loss per share in 2021, 2022 and 2023, as their effect would have been anti-dilutive. The calculation of diluted loss per share as of December 31, 2023 does not include 153,154,860 and 431,954,719 of shares underlying options, and shares underlying warrants, respectively, because the effect would be anti-dilutive.
Leases	m. Leases The Company’s leases include property and motor vehicle leases. At the commencement date, the Company measures the lease liability at the present value of the lease payments that are not paid at that date. Simultaneously, the Company recognizes a right-of-use asset in the amount of the lease liability. Since the interest rate implicit in the lease cannot be readily determined, the Company uses the Company’s incremental borrowing rate. The lease term is the non-cancellable period for which the Company has the right to use an underlying asset, together with both the periods covered by an option to extend the lease, if the Company is reasonably certain to exercise that option, and periods covered by an option to terminate the lease, if the Company is reasonably certain not to exercise that option. After the commencement date, the Company measures the right-of-use asset applying the cost model, less any accumulated depreciation and any accumulated impairment losses and adjusted for any remeasurement of the lease liability. Assets are depreciated by the straight-line method over the estimated useful lives of the right of use assets or the lease period, whichever is shorter, as follows: Years Property 11 Motor vehicles 3
New International Financial Reporting Standards, amendments to standards and new interpretations	n. New International Financial Reporting Standards, amendments to standards and new interpretations: Classification of Liabilities as Current or Non-Current (Amendment to IAS 1) The narrow-scope amendments to IAS 1, “Presentation of Financial Statements,” clarify that liabilities are classified as either current or noncurrent, depending on the rights that exist at the end of the reporting period. Classification is unaffected by the entity’s expectations or events after the reporting date (e.g., the receipt of a waiver or a breach of covenant). The amendments also clarify what IAS 1 means when it refers to the ‘settlement’ of a liability. The amendments could affect the classification of liabilities, particularly for entities that previously considered management’s intentions to determine classification and for some liabilities that can be converted into equity. They must be applied retrospectively in accordance with the normal requirements in IAS 8, “Accounting Policies, Changes in Accounting Estimates and Errors.” The amendment should be applied retrospectively for annual periods beginning on or after January 1, 2024. Earlier application is permitted. The adoption of the amendment is expected to have a material impact on the Company’s financial statements as, effective January 1, 2024, the Company’s warrant liabilities will be classified in current liabilities. Deferred Tax Related to Assets and Liabilities Arising from a Single Transaction (Amendment to IAS 12) The amendment requires companies to recognize deferred tax on transactions that, on initial recognition, give rise to equal amounts of taxable and deductible temporary differences, and will require the recognition of additional deferred tax assets and liabilities. The amendment should be applied to transactions that occur on or after the beginning of the earliest comparative period presented. In addition, entities should recognize deferred tax assets (to the extent that it is probable that they can be utilized) and deferred tax liabilities at the beginning of the earliest comparative period for all deductible and taxable temporary differences associated with right-of-use assets and lease liabilities, decommissioning, restoration and similar liabilities, and the corresponding amounts recognized as part of the cost of the related assets. The adoption of the amendment had no material impact on the Company’s financial statements. Material accounting Policies (Amendment to IAS 1) The amendments change the requirements in IAS 1 with regard to disclosure of accounting policies. The amendments require entities to disclose their material rather than their significant accounting policies. Accounting policy information is material if, when considered together with other information included in an entity’s financial statements, it can reasonably be expected to influence decisions that the primary users of general-purpose financial statements make on the basis of those financial statements. The supporting paragraphs in IAS 1 are also amended to clarify that accounting policy information that relates to immaterial transactions, other events or conditions is immaterial and need not be disclosed. Accounting policy information may be material because of the nature of the related transactions, other events or conditions, even if the amounts are immaterial. However, not all accounting policy information relating to material transactions, other events or conditions is itself material. These financial statements are prepared in accordance with the amendments to IAS 1 as they were effective for annual periods beginning on January 1, 2023.

MATERIAL ACCOUNTING POLICIES (T

MATERIAL ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure of significant accounting policies [Abstract]
Schedule of Depreciation Rates	% Computers and communications equipment 33 Office furniture and equipment 6 Laboratory equipment 15
Schedule of Useful Life of Right of Use Assets	Years Property 11 Motor vehicles 3

FINANCIAL INSTRUMENTS AND FIN_2

FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure of detailed information about financial instruments [abstract]
Schedule of Concentration of Currency Risk	December 31, 2023 Income (loss) Value on Income (loss) Sensitive instrument 10% increase 5% increase balance sheet 5% decrease 10% decrease in USD thousands NIS-linked balances: Cash and cash equivalents (132 ) (69 ) 1,457 77 162 Short term deposit (251 ) (131 ) 2,758 145 306 Other receivables (31 ) (16 ) 344 18 38 Trade payables 243 127 (2,670 ) (141 ) (297 ) Other payables 169 89 (1,853 ) (98 ) (207 ) Total NIS-linked balances (2 ) 0 36 1 2 Euro-linked trade payables (117 ) (61 ) (1,283 ) 67 142 Total (119 ) (61 ) (1,247 ) 68 144 December 31, 2022 Income (loss) Value on Income (loss) Sensitive instrument 10% increase 5% increase balance sheet 5% decrease 10% decrease in USD thousands NIS-linked balances: Cash and cash equivalents (416 ) (218 ) 4,573 241 508 Other receivables (66 ) (34 ) 721 38 80 Trade payables 38 20 (416 ) (22 ) (46 ) Other payables 114 60 (1,257 ) (66 ) (140 ) Total NIS-linked balances (330 ) (172 ) 3,621 191 402 Euro-linked trade payables (144 ) (76 ) (1,590 ) 84 177 Total (474 ) (248 ) 2,031 275 579
Schedule of Linkage of Monetary Items	December 31, 2022 December 31, 2023 Dollar NIS Other currencies Dollar NIS Other Currencies USD in thousands USD in thousands Assets: Current assets: Cash and cash equivalents 5,685 4,573 329 2,768 1,457 30 Short term bank deposits 40,495 - - 35,981 2,758 - Other receivables - 721 - 480 350 - 46,180 5,294 329 39,229 4,565 30 Liabilities: Current liabilities: Current maturities of long-term loans 1,542 - - 3,145 - - Accounts payable and accruals: Trade 4,359 416 2,191 6,663 2,670 1,536 Other 487 1,257 - 1,500 1,853 - Non-current liabilities Long-term loans, net of current maturities 8,626 - - 6,628 - - 15,014 1,673 2,191 17,936 4,523 1,536 Net balance 31,166 3,621 (1,862 ) 21,293 42 (1,506 )
Schedule of Credit Risk	December 31, 2022 2023 in USD thousands Assets: Cash and cash equivalents 10,587 4,255 Short-term bank deposits 40,495 38,739 Trade receivables - 358 Other receivables 721 830 Total 51,803 44,182
Schedule of Changes in Financial Liabilities With Cash Flows Included in Financing Activities	Long-term loans Warrants Total in USD thousands Balance as of January 1, 2021 5,832 10,218 16,050 Changes during the year 2021: Principal and interest payments (3,814 ) - (3,814 ) Share premium resulting from exercise of warrants (10,295 ) (10,295 ) Amounts recognized through profit and loss 739 1,936 2,675 Balance as of December 31, 2021 2,757 1,859 4,616 Changes during the year 2022: Net proceeds 9,126 9,075 18,201 Principal and interest payments (3,177 ) - (3,177 ) Amounts recognized through profit and loss 1,462 (6,425 ) (4,963 ) Balance as of December 31, 2022 10,168 4,509 14,677 Changes during the year 2023: Principal payments or received (1,543 ) - (1,543 ) Amounts recognized through profit and loss 1,148 11,054 12,202 Share premium resulting from exercise of warrants - (3,631 ) (3,631 ) Balance as of December 31, 2023 9,773 11,932 21,705
Schedule of Fair Value Measurement of Warrants	Warrants in USD thousands Balance as of January 1, 2021 10,218 Changes during 2021: Exercises (10,295 ) Changes in fair value through profit and loss 1,936 Balance as of December 31, 2021 1,859 Changes during 2022: Issuances 9,075 Changes in fair value through profit and loss (6,425 ) Balance as of December 31, 2022 4,509 Changes during 2023: Exercises (3,631 ) Changes in fair value through profit and loss 11,054 Balance as of December 31, 2023 11,932

CASH AND CASH EQUIVALENTS (Tabl

CASH AND CASH EQUIVALENTS (Tables)	12 Months Ended
	Dec. 31, 2023
Cash and cash equivalents [abstract]
Schedule of Cash And Cash Equivalents	December 31, 2022 2023 in USD thousands Cash on hand and in bank 3,623 3,154 Short-term bank deposits 6,964 1,101 10,587 4,255

INVENTORY (Tables)

INVENTORY (Tables)	12 Months Ended
	Dec. 31, 2023
Classes of current inventories [abstract]
Schedule of Inventory	December 31, 2022 2023 in USD thousands Raw materials - 903 Work-in-progress - 471 Finished goods - 579 - 1,953

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure of detailed information about property, plant and equipment [abstract]
Schedule of Composition of Property and Equipment and Related Accumulated Depreciation	Cost Accumulated depreciation Balance at Additions Deletions Balance at Balance at Additions Deletions Balance at Net book value beginning during during end of beginning during during end of December 31, of year year year year of year year year year 2022 2023 in USD thousands in USD thousands in USD thousands Composition in 2023 Office furniture and equipment 244 8 - 252 138 27 - 165 106 87 Computers and communications equipment 961 101 - 1,062 712 108 - 820 249 242 Laboratory equipment 1,606 7 - 1,613 1,578 20 - 1,598 28 15 Leasehold improvements 2,036 - - 2,036 1,693 214 - 1,907 343 129 4,847 116 - 4,963 4,121 369 - 4,490 726 473

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure of detailed information about intangible assets [abstract]
Schedule of Intangible Assets	Cost Accumulated depreciation and impairment Balance at Additions Disposal Balance at Balance at Additions Impairment Balance at Net book value beginning during during end of beginning during during end of December 31, of year year year year of year year year year 2022 2023 in USD thousands in USD thousands in USD thousands Composition in 2023 Intellectual property 21,792 - 450 21,342 96 - 6,703 6,799 21,696 14,543 Computer software 801 181 - 982 612 59 - 671 189 311 22,593 181 450 22,324 708 59 6,703 7,470 21,885 14,854

LEASES (Tables)

LEASES (Tables)	12 Months Ended
	Dec. 31, 2023
Presentation of leases for lessee [abstract]
Schedule of Right-of-use assets	Cost Accumulated depreciation Balance at Additions Deletions Balance at Balance at Additions Deletions Balance at Net book value beginning during during end of beginning during during end of December 31, of year year year year of year year year year 2022 2023 in USD thousands in USD thousands in USD thousands Composition in 2023 Property 2,097 - - 2,097 582 388 - 970 1,515 1,127 Motor vehicles 336 149 117 368 79 118 117 80 257 288 2,433 149 117 2,465 661 506 117 1,050 1,772 1,415
Schedule of Lease Liabilities	Balance at Additions Deletions Interest expense Exchange differences Payments Balance at beginning during during during during during end of of year year year year year year year in USD thousands Composition in 2023 Property 1,920 - - 236 (38 ) (562 ) 1,556 Motor vehicles 236 149 - 37 (4 ) (156 ) 262 2,156 149 - 273 (42 ) (718 ) 1,818
Schedule of Minimum Future Rental Payments	Year Property Motor vehicles Total in USD thousands 2024 575 161 736 2025 292 113 405 2026 292 26 317 2027 306 - 306 2028-2030 766 - 766 2,231 300 2,531

EQUITY (Tables)

EQUITY (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure of classes of share capital [abstract]
Schedule of Share Capital	Number of Ordinary Shares December 31, 2022 2023 Authorized share capital 2,500,000,000 2,500,000,000 Issued and paid-up share capital 922,958,942 1,086,589,165 In USD and NIS Amounts December 31, 2022 2023 Authorized share capital (in NIS) 250,000,000 250,000,000 Issued and paid-up share capital (in NIS) 92,295,894 108,658,916 Issued and paid-up share capital (in USD) 27,100,201 31,355,056
Schedule of Amounts Outstanding Under Employee Share Incentive Plan	Year ended December 31, 2021 2022 2023 Number of options Weighted average exercise price (in NIS) Number of options Weighted average exercise price (in NIS) Number of options Weighted average exercise price (in NIS) Outstanding at beginning of year 35,981,579 1.5 40,956,214 0.7 89,871,858 0.4 Granted 6,588,200 0.4 53,696,305 0.3 64,855,380 0.2 Forfeited and expired (1,438,642 ) 3.0 (4,618,062 ) 0.8 (3,804,175 ) 0.7 Exercised (174,923 ) 0.1 (162,599 ) 0.1 (493,238) 0.2 Outstanding at end of year* 40,956,214 0.7 89,871,858 0.4 150,429,825 0.3 Exercisable at end of year 18,663,353 1.7 26,663,961 0.8 51,970,635 0.5 * As of December 31, 2021, 2022 and 2023, includes 4,084,748, 10,482,277, and 12,219,465 PSUs at an exercise price of 0.10 NIS (par value of ordinary shares), for which performance obligations have not been met.
Schedule of Options Outstanding by Exercise Price Range	As of December 31, 2022 2023 Range of exercise prices (in NIS) Number of options outstanding Weighted average remaining contractual life (in yrs.) Number of options outstanding Weighted average remaining contractual life (in yrs.) Up to 0.49 58,488,372 9.2 120,593,415 8.8 0.5-0.99 17,175,120 7.8 16,147,110 6.9 1.00-2.00 13,668,366 5.5 13,149,390 4.7 2.01-3.4 540,000 4.2 539,910 3.2 89,871,858 8.4 150,429,825 8.2
Schedule of Assumptions Used to Value Options	2021 2022 2023 Expected dividend yield 0 % 0 % 0 % Expected volatility 67 % 67 % 69 % Risk-free interest rate 1 % 4 % 4 % Expected life of options (in years) 6 6 6

TAXES ON INCOME (Tables)

TAXES ON INCOME (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure Of Income Taxes [Abstract]
Schedule of Reconciliation of Weighted Average Tax Rate Applicable to Income	Year ended December 31, 2021 2022 2023 in USD in USD in USD thousands thousands thousands Loss before taxes 23.0 % (27,045 ) 23.0 % (24,951 ) 23.0 % (60,614 ) Theoretical tax benefit (6,220 ) (5,739 ) (13,941 ) Disallowed deductions (tax exempt income): Loss (gain) on adjustment of warrants to fair value 480 (1,478 ) 2,542 Share-based compensation 343 516 534 Impairment of intangible asset - - 1,542 Other 11 11 11 Increase in taxes for tax losses and timing differences incurred in the reporting year for which deferred taxes were not created 5,386 6,690 9,312 Taxes on income for the reported year - - -

LOSS PER SHARE (Tables)

LOSS PER SHARE (Tables)	12 Months Ended
	Dec. 31, 2023
Earnings per share [abstract]
Schedule of Basic Loss Per Share	Year ended December 31, 2021 2022 2023 in USD thousands Loss attributed to ordinary shares (27,054 ) (24,951 ) (60,614 ) in thousands Number of shares used in basic calculation 662,934 773,957 963,366 in USD Basic and diluted loss per ordinary share (0.04 ) (0.03 ) (0.06 )

TRANSACTIONS AND BALANCES WIT_2

TRANSACTIONS AND BALANCES WITH RELATED PARTIES (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure of transactions between related parties [abstract]
Schedule of Transactions With Related Parties	Year ended December 31, 2021 2022 2023 in USD thousands Benefits to related parties: Compensation and benefits to senior management, including benefit component of equity instrument grants 2,302 2,968 3,155 Compensation and benefits to directors, including benefit component of equity instrument grants 300 507 587
Schedule of Key Management Compensation	Year ended December 31, 2021 2022 2023 in USD thousands Salaries and other short-term employee benefits 1,883 2,298 2,425 Post-employment benefits 136 131 256 Other long-term benefits 35 35 31 Share-based compensation 548 1,011 1,030 2,602 3,475 3,742

SUPPLEMENTARY FINANCIAL STATE_2

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2023
Disclosure of supplementary financial statement information [Abstract]
Schedule of Other Receivables	December 31, 2022 2023 in USD thousands Advance payments - 480 Government institutions 687 245 Other 34 105 721 830
Schedule of Accounts Payable and Accruals	December 31, 2022 2023 in USD thousands 1) Trade: Accounts payable: Overseas 6,061 7,704 In Israel 905 3,165 6,966 10,869 2) Other: Payroll and related expenses 931 2,184 Accrued expenses 352 662 Accrual for vacation and recreation pay 377 419 Other 84 88 1,744 3,353
Schedule of Revenues	Year ended December 31, 2021 2022 2023 in USD thousands License revenues (see Note 16) - - 4,610 Product sales, net - - 190 - - 4,800
Schedule of Cost of Revenues	Year ended December 31, 2021 2022 2023 in USD thousands Cost related to license revenues - - 3,230 Amortization of intangible asset in respect of license revenues - - 450 Cost of product sales - - 12 - - 3,692
Schedule of Research and Development Expenses	Year ended December 31, 2021 2022 2023 in USD thousands Research and development services 12,088 9,296 4,603 Payroll and related expenses 4,074 4,495 4,452 Lab, occupancy and telephone 882 902 969 Professional fees 595 954 935 Share-based compensation 971 1,198 760 Depreciation and amortization 660 615 583 Other 196 169 217 19,466 17,629 12,519
Schedule of Sales and Marketing Expenses	Year ended December 31, 2021 2022 2023 in USD thousands Payroll and related expenses 308 947 8,868 Medical Affairs - 1,316 4,824 Marketing 700 1,805 4,091 Office related expenses - 519 1,923 Market Access - 1,023 1,606 Business Analytics - 106 1,005 Travel 25 84 986 Share-based compensation (59 ) 112 751 Professional fees - 521 745 Depreciation and amortization - - 314 Other 29 29 158 1,003 6,462 25,270
Schedule of General and Administrative Expenses	Year ended December 31, 2021 2022 2023 in USD thousands Payroll and related expenses 1,408 1,706 2,117 Professional fees 1,103 1,248 2,028 Insurance 1,064 1,046 939 Share-based compensation 583 895 780 Depreciation 42 39 37 Other 108 132 409 4,308 5,066 6,310
Schedule of Non-Operating Income (Expenses), Net	Year ended December 31, 2021 2022 2023 in USD thousands Changes in fair value of warrants (1,936 ) 6,425 (11,054 ) Issuance costs - (762 ) - Other 106 7 235 (1,830 ) 5,670 (10,819 )
Schedule of Financial Income	Year ended December 31, 2021 2022 2023 in USD thousands Interest income 277 694 2,007 Exchange differences, net 282 - 61 559 694 2,068
Schedule of Financial Expenses	Year ended December 31, 2021 2022 2023 in USD thousands Interest expense 984 1,786 2,144 Bank commissions 22 26 25 Exchange differences, net - 346 - 1,006 2,158 2,169

GENERAL INFORMATION (Narrative)

GENERAL INFORMATION (Narrative) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Disclosure of general information [Abstract]
Accumulated deficit	$ (390,606)	$ (329,992)

MATERIAL ACCOUNTING POLICIES (N

MATERIAL ACCOUNTING POLICIES (Narrative) (Details)	12 Months Ended
	Dec. 31, 2023 shares
Computer software [Member]
Disclosure of detailed information about intangible assets [line items]
Estimated useful lives of intangible assets (In years)	5 years
Share options [member]
Disclosure of detailed information about intangible assets [line items]
Diluted loss per share	153,154,860
Warrants [member]
Disclosure of detailed information about intangible assets [line items]
Diluted loss per share	431,954,719

MATERIAL ACCOUNTING POLICIES (S

MATERIAL ACCOUNTING POLICIES (Schedule of Depreciation Rates) (Details) - Net Book Value [Member]	12 Months Ended
	Dec. 31, 2023
Computers and communications equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation rates (in %)	33
Office furniture and equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation rates (in %)	6
Laboratory equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation rates (in %)	15

MATERIAL ACCOUNTING POLICIES _2

MATERIAL ACCOUNTING POLICIES (Schedule of Useful Life of Right of Use Assets) (Details)	12 Months Ended
	Dec. 31, 2023
Property [member]
Disclosure of quantitative information about right-of-use assets [line items]
Estimated useful lives or lease period of right of use assets	11
Motor vehicles [member]
Disclosure of quantitative information about right-of-use assets [line items]
Estimated useful lives or lease period of right of use assets	3

FINANCIAL INSTRUMENTS AND FIN_3

FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Narrative) (Details)	Dec. 31, 2023 USD ($)
Warrants [member]
Disclosure of financial liabilities [line items]
Fair value of the warrants	$ 11,932,000

FINANCIAL INSTRUMENTS AND FIN_4

FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Sensitivity Analysis) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Cash and cash equivalents [Member]
Disclosure of detailed information about financial instruments [line items]
10% increase effect on net income (loss) and equity	$ (132)	$ (416)
5% increase effect on net income (loss) and equity	(69)	(218)
Value on balance sheet	1,457	4,573
5% decrease effect on net income (loss) and equity	77	241
10% decrease effect on net income (loss) and equity	162	508
Short Term Deposit [Member]
Disclosure of detailed information about financial instruments [line items]
10% increase effect on net income (loss) and equity	(251)
5% increase effect on net income (loss) and equity	(131)
Value on balance sheet	2,758
5% decrease effect on net income (loss) and equity	145
10% decrease effect on net income (loss) and equity	306
Other receivables [Member]
Disclosure of detailed information about financial instruments [line items]
10% increase effect on net income (loss) and equity	(31)	(66)
5% increase effect on net income (loss) and equity	(16)	(34)
Value on balance sheet	344	721
5% decrease effect on net income (loss) and equity	18	38
10% decrease effect on net income (loss) and equity	38	80
Trade payables [Member]
Disclosure of detailed information about financial instruments [line items]
10% increase effect on net income (loss) and equity	243	38
5% increase effect on net income (loss) and equity	127	20
Value on balance sheet	(2,670)	(416)
5% decrease effect on net income (loss) and equity	(141)	(22)
10% decrease effect on net income (loss) and equity	(297)	(46)
Other payables [Member]
Disclosure of detailed information about financial instruments [line items]
10% increase effect on net income (loss) and equity	169	114
5% increase effect on net income (loss) and equity	89	60
Value on balance sheet	(1,853)	(1,257)
5% decrease effect on net income (loss) and equity	(98)	(66)
10% decrease effect on net income (loss) and equity	(207)	(140)
NIS-linked balances [Member]
Disclosure of detailed information about financial instruments [line items]
10% increase effect on net income (loss) and equity	(2)	(330)
5% increase effect on net income (loss) and equity	0	(172)
Value on balance sheet	36	3,621
5% decrease effect on net income (loss) and equity	1	191
10% decrease effect on net income (loss) and equity	2	402
Euro-linked trade payables [Member]
Disclosure of detailed information about financial instruments [line items]
10% increase effect on net income (loss) and equity	(117)	(144)
5% increase effect on net income (loss) and equity	(61)	(76)
Value on balance sheet	(1,283)	(1,590)
5% decrease effect on net income (loss) and equity	67	84
10% decrease effect on net income (loss) and equity	142	177
Total [Member]
Disclosure of detailed information about financial instruments [line items]
10% increase effect on net income (loss) and equity	(119)	(474)
5% increase effect on net income (loss) and equity	(61)	(248)
Value on balance sheet	1,247	2,031
5% decrease effect on net income (loss) and equity	68	275
10% decrease effect on net income (loss) and equity	$ 144	$ 579

FINANCIAL INSTRUMENTS AND FIN_5

FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Linkage of Monetary Items) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 4,255	$ 10,587	$ 12,990	$ 16,831
Total assets	63,925	76,384
Current liabilities:
Current maturities of long-term loans	3,145	1,542
Accounts payable and accruals:
Trade	10,869	6,966
Other	88	84
Non-current liabilities
Long-term loans, net of current maturities	6,628	8,626
Total liabilities	50,702	25,543
Dollar [Member]
Current assets:
Cash and cash equivalents	2,768	5,685
Short term bank deposits	35,981	40,495
Other receivables	480	0
Total assets	39,229	46,180
Current liabilities:
Current maturities of long-term loans	3,145	1,542
Accounts payable and accruals:
Trade	6,663	4,359
Other	1,500	487
Non-current liabilities
Long-term loans, net of current maturities	6,628	8,626
Total liabilities	17,936	15,014
Net asset value	21,293	31,166
NIS [Member]
Current assets:
Cash and cash equivalents	1,457	4,573
Short term bank deposits	2,758	0
Other receivables	350	721
Total assets	4,565	5,294
Current liabilities:
Current maturities of long-term loans	0	0
Accounts payable and accruals:
Trade	2,670	416
Other	1,853	1,257
Non-current liabilities
Long-term loans, net of current maturities	0	0
Total liabilities	4,523	1,673
Net asset value	42	3,621
Other currencies [Member]
Current assets:
Cash and cash equivalents	30	329
Short term bank deposits	0	0
Other receivables	0	0
Total assets	30	329
Current liabilities:
Current maturities of long-term loans	0	0
Accounts payable and accruals:
Trade	1,536	2,191
Other	0	0
Non-current liabilities
Long-term loans, net of current maturities	0	0
Total liabilities	1,536	2,191
Net asset value	$ (1,506)	$ (1,862)

FINANCIAL INSTRUMENTS AND FIN_6

FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Credit Risk) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Assets:
Cash and cash equivalents	$ 4,255	$ 10,587	$ 12,990	$ 16,831
Trade receivables	358	0
Total assets	63,925	76,384
Credit risk [member]
Assets:
Cash and cash equivalents	4,255	10,587
Short-term bank deposits	38,739	40,495
Trade receivables	358	0
Other receivables	830	721
Total assets	$ 44,182	$ 51,803

FINANCIAL INSTRUMENTS AND FIN_7

FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Changes in Financial Liabilities With Cash Flows) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Balance as of January 1	$ 14,677	$ 4,616	$ 16,050
Changes during the year:
Net proceeds of loan		18,201
Principal and interest payments	(1,543)	3,177	(3,814)
Share premium resulting from exercise of warrants	(3,631)		(10,295)
Amounts recognized through profit and loss	12,202	(4,963)	2,675
Balance as of December 31	21,705	14,677	4,616
Long-term loans [member]
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Balance as of January 1	10,168	2,757	5,832
Changes during the year:
Net proceeds of loan		9,126
Principal and interest payments	(1,543)	(3,177)	(3,814)
Share premium resulting from exercise of warrants	0
Amounts recognized through profit and loss	1,148	1,462	739
Balance as of December 31	9,773	10,168	2,757
Warrants [member]
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Balance as of January 1	4,509	1,859	10,218
Changes during the year:
Net proceeds of loan		9,075
Principal and interest payments	0	0	0
Share premium resulting from exercise of warrants	(3,631)		(10,295)
Amounts recognized through profit and loss	(11,054)	(6,425)	1,936
Balance as of December 31	$ 11,932	$ 4,509	$ 1,859

FINANCIAL INSTRUMENTS AND FIN_8

FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Schedule of Fair Value Measurement of Warrants) (Details) - Level 3 of fair value hierarchy [member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Balance as of January 1	$ 4,509	$ 1,859	$ 10,218
Issuances		9,075
Exercises	(3,631)		(10,295)
Changes in fair value through profit and loss	11,054	(6,425)	1,936
Balance as of December 31	$ 11,932	$ 4,509	$ 1,859

CASH AND CASH EQUIVALENTS (Narr

CASH AND CASH EQUIVALENTS (Narrative) (Details)	12 Months Ended
	Dec. 31, 2023
Bottom of range [member]
Disclosure of detailed information about financial instruments [line items]
Interest rate on short-term deposits	0.15%
Top of range [member]
Disclosure of detailed information about financial instruments [line items]
Interest rate on short-term deposits	4.55%

CASH AND CASH EQUIVALENTS (Sche

CASH AND CASH EQUIVALENTS (Schedule of Cash And Cash Equivalents) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash and cash equivalents [abstract]
Cash on hand and in bank	$ 3,154	$ 3,623
Short-term bank deposits	1,101	6,964
Cash and cash equivalents	$ 4,255	$ 10,587	$ 12,990	$ 16,831

SHORT-TERM BANK DEPOSITS (Narra

SHORT-TERM BANK DEPOSITS (Narrative) (Details)	12 Months Ended
	Dec. 31, 2023
Bottom of range [member]
Disclosure of detailed information about financial instruments [line items]
Interest rate on short-term deposits	0.57%
Top of range [member]
Disclosure of detailed information about financial instruments [line items]
Interest rate on short-term deposits	6.63%

INVENTORY (Schedule of Inventor

INVENTORY (Schedule of Inventory) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Classes of current inventories [abstract]
Raw materials	$ 903	$ 0
Work-in-progress	471	0
Finished goods	579	0
Total Inventory	$ 1,953	$ 0

PROPERTY AND EQUIPMENT (Schedul

PROPERTY AND EQUIPMENT (Schedule of Composition of Property and Equipment and Related Accumulated Depreciation) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year	$ 726
Balance at end of year	473
Cost [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year	4,847
Additions during year	116
Deletions during year	0
Balance at end of year	4,963
Cost [Member] | Office furniture and equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year	244
Additions during year	8
Deletions during year	0
Balance at end of year	252
Cost [Member] | Computers and communications equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year	961
Additions during year	101
Deletions during year	0
Balance at end of year	1,062
Cost [Member] | Laboratory equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year	1,606
Additions during year	7
Deletions during year	0
Balance at end of year	1,613
Cost [Member] | Leasehold improvements [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year	2,036
Additions during year	0
Deletions during year	0
Balance at end of year	2,036
Accumulated depreciation [member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year	4,121
Additions during year	369
Deletions during year	0
Balance at end of year	4,490
Accumulated depreciation [member] | Office furniture and equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year	138
Additions during year	27
Deletions during year	0
Balance at end of year	165
Accumulated depreciation [member] | Computers and communications equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year	712
Additions during year	108
Deletions during year	0
Balance at end of year	820
Accumulated depreciation [member] | Laboratory equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year	1,578
Additions during year	20
Deletions during year	0
Balance at end of year	1,598
Accumulated depreciation [member] | Leasehold improvements [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year	1,693
Additions during year	214
Deletions during year	0
Balance at end of year	1,907
Net Book Value [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year	726
Balance at end of year	473
Net Book Value [Member] | Office furniture and equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year	106
Balance at end of year	87
Net Book Value [Member] | Computers and communications equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year	249
Balance at end of year	242
Net Book Value [Member] | Laboratory equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year	28
Balance at end of year	15
Net Book Value [Member] | Leasehold improvements [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning of year	343
Balance at end of year	$ 129

INTANGIBLE ASSETS (Narrative) (

INTANGIBLE ASSETS (Narrative) (Details) - Intellectual property [Member] $ in Millions	12 Months Ended
	Dec. 31, 2023 USD ($)
Agalimmune Ltd. [Member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets acquired	$ 6.7
Biokine Therapeutics Ltd [Member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets acquired	$ 15
Percentage of payment to be made	40% to 20%

INTANGIBLE ASSETS (Schedule of

INTANGIBLE ASSETS (Schedule of Intangible Assets) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)
Disclosure of detailed information about intangible assets [line items]
Balance at beginning of year	$ 21,885
Balance at end of year	14,854
Net Book Value [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning of year	21,885
Balance at end of year	14,854
Net Book Value [Member] | Intellectual property [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning of year	21,696
Balance at end of year	14,543
Net Book Value [Member] | Computer software [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning of year	189
Balance at end of year	311
Cost [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning of year	22,593
Additions during year	181
Deletions during year	450
Balance at end of year	22,324
Cost [Member] | Intellectual property [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning of year	21,792
Additions during year	0
Deletions during year	450
Balance at end of year	21,342
Cost [Member] | Computer software [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning of year	801
Additions during year	181
Deletions during year	0
Balance at end of year	982
Accumulated depreciation and impairment [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning of year	708
Additions during year	59
Deletions during year	6,703
Balance at end of year	7,470
Accumulated depreciation and impairment [Member] | Intellectual property [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning of year	96
Additions during year	0
Deletions during year	6,703
Balance at end of year	6,799
Accumulated depreciation and impairment [Member] | Computer software [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning of year	612
Additions during year	59
Deletions during year	0
Balance at end of year	$ 671

LEASES (Narrative) (Details)

LEASES (Narrative) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($) Premises
Disclosure Of Leases [Line Items]
Number of premises | Premises	2
Lease Period	3 years
Annual Lease fee	$ 303,000
Israel [Member]
Disclosure Of Leases [Line Items]
Lease agreement monthly fee	$ 25,000
Additional extension period	five
Percentage Increase preceding lease payment amount	5%
Building maintenance charges	$ 8,000
Boston [Member]
Disclosure Of Leases [Line Items]
Lease agreement monthly fee	$ 24,000

LEASES (Schedule of Right-of-us

LEASES (Schedule of Right-of-use assets) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)
Disclosure of quantitative information about right-of-use assets [line items]
Balance at beginning of year	$ 1,772
Balance at end of year	1,415
Net book value [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Balance at beginning of year	1,772
Balance at end of year	1,415
Net book value [Member] | Property [member]
Disclosure of quantitative information about right-of-use assets [line items]
Balance at beginning of year	1,515
Balance at end of year	1,127
Net book value [Member] | Motor vehicles [member]
Disclosure of quantitative information about right-of-use assets [line items]
Balance at beginning of year	257
Balance at end of year	288
Cost [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Balance at beginning of year	2,433
Additions during year	149
Deletions during year	117
Balance at end of year	2,465
Cost [Member] | Property [member]
Disclosure of quantitative information about right-of-use assets [line items]
Balance at beginning of year	2,097
Additions during year	0
Deletions during year	0
Balance at end of year	2,097
Cost [Member] | Motor vehicles [member]
Disclosure of quantitative information about right-of-use assets [line items]
Balance at beginning of year	336
Additions during year	149
Deletions during year	117
Balance at end of year	368
Accumulated depreciation [member]
Disclosure of quantitative information about right-of-use assets [line items]
Balance at beginning of year	(661)
Additions during year	506
Deletions during year	117
Balance at end of year	(1,050)
Accumulated depreciation [member] | Property [member]
Disclosure of quantitative information about right-of-use assets [line items]
Balance at beginning of year	(582)
Additions during year	388
Deletions during year	0
Balance at end of year	(970)
Accumulated depreciation [member] | Motor vehicles [member]
Disclosure of quantitative information about right-of-use assets [line items]
Balance at beginning of year	(79)
Additions during year	118
Deletions during year	117
Balance at end of year	$ (80)

LEASES (Schedule of Lease Liabi

LEASES (Schedule of Lease Liabilities) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)
Disclosure Of Quantitative Information About Lease Liabilities [Line Items]
Balance at beginning of year	$ 2,156
Additions during year	149
Deletions during year	0
Interest expense during year	273
Exchange differences during year	(42)
Payments during year	(718)
Balance at end of year	1,818
Property [member]
Disclosure Of Quantitative Information About Lease Liabilities [Line Items]
Balance at beginning of year	1,920
Additions during year	0
Deletions during year	0
Interest expense during year	236
Exchange differences during year	(38)
Payments during year	(562)
Balance at end of year	1,556
Motor vehicles [member]
Disclosure Of Quantitative Information About Lease Liabilities [Line Items]
Balance at beginning of year	236
Additions during year	149
Deletions during year	0
Interest expense during year	37
Exchange differences during year	(4)
Payments during year	(156)
Balance at end of year	$ 262

LEASES (Schedule of Minimum Fut

LEASES (Schedule of Minimum Future Rental Payments) (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Disclosure of maturity analysis of operating lease payments [line items]
Minimum future rental payments	$ 2,531
Property [member]
Disclosure of maturity analysis of operating lease payments [line items]
Minimum future rental payments	2,231
Motor vehicles [member]
Disclosure of maturity analysis of operating lease payments [line items]
Minimum future rental payments	300
2024 [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Minimum future rental payments	736
2024 [Member] | Property [member]
Disclosure of maturity analysis of operating lease payments [line items]
Minimum future rental payments	575
2024 [Member] | Motor vehicles [member]
Disclosure of maturity analysis of operating lease payments [line items]
Minimum future rental payments	161
2025 [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Minimum future rental payments	405
2025 [Member] | Property [member]
Disclosure of maturity analysis of operating lease payments [line items]
Minimum future rental payments	292
2025 [Member] | Motor vehicles [member]
Disclosure of maturity analysis of operating lease payments [line items]
Minimum future rental payments	113
2026 [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Minimum future rental payments	317
2026 [Member] | Property [member]
Disclosure of maturity analysis of operating lease payments [line items]
Minimum future rental payments	292
2026 [Member] | Motor vehicles [member]
Disclosure of maturity analysis of operating lease payments [line items]
Minimum future rental payments	26
2027 [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Minimum future rental payments	306
2027 [Member] | Property [member]
Disclosure of maturity analysis of operating lease payments [line items]
Minimum future rental payments	306
2027 [Member] | Motor vehicles [member]
Disclosure of maturity analysis of operating lease payments [line items]
Minimum future rental payments	0
2028-2030 [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Minimum future rental payments	766
2028-2030 [Member] | Property [member]
Disclosure of maturity analysis of operating lease payments [line items]
Minimum future rental payments	766
2028-2030 [Member] | Motor vehicles [member]
Disclosure of maturity analysis of operating lease payments [line items]
Minimum future rental payments	$ 0

LONG-TERM LOANS (Narrative) (De

LONG-TERM LOANS (Narrative) (Details) - USD ($) $ in Millions	1 Months Ended	13 Months Ended
	Oct. 31, 2018	Sep. 30, 2022
Disclosure of detailed information about borrowings [line items]
Loan taken from Kreos Capital for the payment	$ 10
Loan Agreement With Kreos Capital [Member]
Disclosure of detailed information about borrowings [line items]
Amount of loan agreement		$ 40
Loan Agreement With Kreos Capital [Member] | Bottom of range [member]
Disclosure of detailed information about borrowings [line items]
Percentage of annual interest of cash fees		9.50%
Loan Agreement With Kreos Capital [Member] | Top of range [member]
Disclosure of detailed information about borrowings [line items]
Percentage of annual interest of cash fees		11%
Loan Agreement With Kreos Capital [Member] | First tranche [Member]
Disclosure of detailed information about borrowings [line items]
Amount of loan agreement		$ 10
Loan Agreement With Kreos Capital [Member] | Second tranche [Member]
Disclosure of detailed information about borrowings [line items]
Amount of loan agreement		$ 30

EQUITY (Narrative) (Details)

EQUITY (Narrative) (Details)	1 Months Ended								4 Months Ended	12 Months Ended
	Aug. 27, 2023 USD ($) $ / shares shares	Sep. 30, 2022 USD ($) $ / shares shares	Sep. 30, 2021 USD ($)	Jan. 31, 2021 USD ($) $ / shares shares	Sep. 30, 2020 USD ($) shares	Jun. 30, 2020 USD ($) $ / shares shares	Feb. 28, 2019 USD ($) $ / shares shares	Oct. 31, 2018 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) shares	Dec. 31, 2023 USD ($) shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2021 Share ₪ / shares shares	Dec. 31, 2021 USD ($)	Dec. 31, 2023 ₪ / shares	Dec. 31, 2023 USD ($) Share shares	Dec. 31, 2022 Share ₪ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Change in fair value										$ 4,573,000	$ 11,033,000
Underwritten public offering | shares				14,375,000			1,866,667
Public offering price | $ / shares				$ 2.4			$ 8.25
Proceeds from public offering, gross							$ 15,400,000
Proceeds from public offering, net							$ 14,100,000
Share issue related cost										0	762,000		$ 0
Gross proceeds										$ 14,089,000	$ 14,359,000		$ 50,407,000
Remaining authorized unissued ordinary shares | shares															17,700,000
Option outstanding | Share															150,429,825	89,871,858
Weighted average contractual life										8 years 2 months 12 days	8 years 4 months 24 days
Risk-free interest rate (%)										4%	4%		1%
Average standard deviation										69%	67%		67%
Remaining unrecognized deferred compensation expense										$ 2,700,000
Compensation cost										3,742,000	$ 3,475,000		$ 2,602,000
ADSs [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise Price Of Share Issued | $ / shares	$ 2.136
Share issue related cost	$ 900,000									$ 700,000
Gross proceeds	$ 14,600,000
Ordinary shares, issued | shares	6,829,137
Recognized as equity	$ 12,000,000
H C Wainwright And Co Llc [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Non operating expense			$ 100,000		$ 200,000
Gross proceeds		$ 2,900,000			$ 24,500,000				$ 4,400,000		$ 18,500,000
Sale of stock | shares					7,381,101				2,109,858	1,501,207	4,745,368
Aggregate offering price			$ 25,000,000		$ 25,000,000
Percentage of commission on sales agreement					3%
2003 Plan [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Ordinary shares, issued | shares															153,154,860
Option vested										8,336,970
Performance Shares Unit [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Option outstanding | Share												4,084,748			12,219,465	10,482,277
Weighted average exercise price outstanding | ₪ / shares												₪ 0.1		₪ 0.1		₪ 0.1
Warrant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise Price Of Share Issued | $ / shares						$ 1.75	$ 11.25
Change in fair value						$ 5,700,000	$ 5,000,000
Exercisable term of warrant							five years
Share issue related cost							$ 400,000
Options exercised										5,739,741	5,739,741
Fair value of the warrants															$ 1,253,000
Registered direct offerings sales | shares						7,653,145
Warrants expiration period						two and half years
Exercise price of warrants | $ / shares						$ 2.25
Warrant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Fair value of the warrants															$ 1,000,000
Risk-free interest rate (%)										0.45%
Average standard deviation										73.80%
Aggregate offering price				$ 34,500,000
Warrants issued to purchase shares | shares				718,750
Warrants expiration period				five years
Exercise price of warrants | $ / shares				$ 3
Proceeds from warrant issue, net				$ 31,400,000
Warrant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise Price Of Share Issued | $ / shares		$ 1.1
Amount allocated to warrant		$ 800,000
Change in fair value		$ 9,100,000								$ 11,905,000	$ 4,502,000
Risk-free interest rate (%)		3.62%								3.90%
Average standard deviation		82.50%								86.50%
Registered direct offerings sales | shares		13,636,365
Warrants expiration period		five years
Exercise price of warrants | $ / shares		$ 1.15
Consultants [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Ordinary shares, issued | shares												3,296,523
Weighted average exercise price | ₪ / shares												₪ 5.23
Option vested and exercised										The options to consultants generally vest over four years and may be exercised for periods of between five and ten years.
Option outstanding | Share															2,725,035
Weighted average contractual life										6 years 10 months 24 days
Weighted average exercise price outstanding | ₪ / shares														₪ 1.01
Loan Agreement With Kreos Capital [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Shares issued to purchase warrant | shares								63,837
Exercise Price Of Share Issued | $ / shares								$ 14.1
Loan Agreement With Kreos Capital [Member] | Warrant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Change in fair value										$ 21,000	36,000
Fair value of the warrants								$ 861,000
Risk-free interest rate (%)								3.84%
Average standard deviation								84.70%
Loan Agreement With Kreos Capital [Member] | Warrant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Change in fair value											$ 563,000
Investors [Member] | Warrant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Warrants issued to purchase shares | shares						7,653,145
Investors [Member] | Warrant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Warrants issued to purchase shares | shares		13,636,365
Placement Agent's Designees [Member] | Warrant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Amount allocated to warrant						$ 600,000
Aggregate offering price						$ 13,400,000
Warrants issued to purchase shares | shares						382,657
Warrants expiration period						two and half years
Exercise price of warrants | $ / shares						$ 2.1875
Proceeds from warrant issue, net						$ 12,000,000
Placement Agent's Designees [Member] | Warrant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Amount allocated to warrant		$ 400,000
Aggregate offering price		$ 15,000,000
Warrants issued to purchase shares | shares		681,818
Warrants expiration period		five years
Exercise price of warrants | $ / shares		$ 1.375
Proceeds from warrant issue, net		$ 13,500,000
Warrants [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Fair value of the warrants															$ 11,932,000
Warrants issued to purchase shares | shares										2,545,455

EQUITY (Schedule of Share Capit

EQUITY (Schedule of Share Capital) (Details)	Dec. 31, 2023 ILS (₪) shares	Dec. 31, 2023 USD ($) shares	Dec. 31, 2022 ILS (₪) shares	Dec. 31, 2022 USD ($) shares
Number of Ordinary Shares
Authorized share capital	2,500,000,000	2,500,000,000	2,500,000,000	2,500,000,000
Issued and paid-up share capital	1,086,589,165	1,086,589,165	922,958,942	922,958,942
Authorized share capital | ₪	₪ 250,000,000		₪ 250,000,000
Issued and paid-up share capital	₪ 108,658,916	$ 31,355,056	₪ 92,295,894	$ 27,100,201

EQUITY (Schedule of Amounts Out

EQUITY (Schedule of Amounts Outstanding Under Employee Share Incentive Plan) (Details)	12 Months Ended
	Dec. 31, 2023 Share ₪ / shares	Dec. 31, 2022 Share ₪ / shares	Dec. 31, 2021 Share ₪ / shares
Number of options
Outstanding at beginning of year	89,871,858
Outstanding at end of year	150,429,825	89,871,858
Employees and Directors [Member]
Number of options
Outstanding at beginning of year	89,871,858	40,956,214	35,981,579
Granted	64,855,380	53,696,305	6,588,200
Forfeited and expired	(3,804,175)	(4,618,062)	(1,438,642)
Exercised	(493,238)	(162,599)	(174,923)
Outstanding at end of year	150,429,825	89,871,858	40,956,214
Exercisable at end of year	51,970,635	26,663,961	18,663,353
Weighted average exercise price (in NIS)
Outstanding at beginning of year | ₪ / shares	₪ 0.4	₪ 0.7	₪ 1.5
Granted | ₪ / shares	0.2	0.3	0.4
Forfeited and expired | ₪ / shares	0.7	0.8	3
Exercised | ₪ / shares	0.2	0.1	0.1
Outstanding at end of year | ₪ / shares	0.3	0.4	0.7
Exercisable at end of year | ₪ / shares	₪ 0.5	₪ 0.8	₪ 1.7

EQUITY (Schedule of Options Out

EQUITY (Schedule of Options Outstanding by Exercise Price Range) (Details) - Share	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number of options outstanding	150,429,825	89,871,858
Weighted average remaining contractual (in yrs.)	8 years 2 months 12 days	8 years 4 months 24 days
Up to 0.49 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number of options outstanding	120,593,415	58,488,372
Weighted average remaining contractual (in yrs.)	8 years 9 months 18 days	9 years 2 months 12 days
0.5- 0.99 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number of options outstanding	16,147,110	17,175,120
Weighted average remaining contractual (in yrs.)	6 years 10 months 24 days	7 years 9 months 18 days
1.00-2.00 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number of options outstanding	13,149,390	13,668,366
Weighted average remaining contractual (in yrs.)	4 years 8 months 12 days	5 years 6 months
2.01-3.4 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number of options outstanding	539,910	540,000
Weighted average remaining contractual (in yrs.)	3 years 2 months 12 days	4 years 2 months 12 days

EQUITY (Schedule of Assumptions

EQUITY (Schedule of Assumptions Used to Value Options) (Details) - Year	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of classes of share capital [abstract]
Expected dividend yield (%)	0%	0%	0%
Expected volatility (%)	69%	67%	67%
Risk-free interest rate (%)	4%	4%	1%
Expected life of options (in years)	6	6	6

TAXES ON INCOME (Narrative) (De

TAXES ON INCOME (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of non-adjusting events after reporting period [line items]
Corporate tax rate	23%	23%	23%
Withholding income tax rate	21%
Tax loss carryforwards	$ 304

TAXES ON INCOME (Schedule of Re

TAXES ON INCOME (Schedule of Reconciliation of Weighted Average Tax Rate Applicable to Income) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Income Taxes [Abstract]
Loss before taxes (Percentage)	23%	23%	23%
Loss before taxes	$ (60,614)	$ (24,951)	$ (27,045)
Theoretical tax benefit	(13,941)	(5,739)	(6,220)
Disallowed deductions (tax exempt income):
Loss (gain) on adjustment of warrants to fair value	2,542	(1,478)	480
Share-based compensation	534	516	343
Impairment of intangible asset	1,542	0	0
Other	11	11	11
Increase in taxes for tax losses and timing differences incurred in the reporting year for which deferred taxes were not created	9,312	6,690	5,386
Taxes on income for the reported year	$ 0	$ 0	$ 0

LOSS PER SHARE (Schedule of Bas

LOSS PER SHARE (Schedule of Basic Loss Per Share) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Earnings per share [abstract]
Loss attributed to ordinary shares	$ (60,614)	$ (24,951)	$ (27,054)
Number of shares used in basic calculation	963,365,525	773,956,973	662,933,695
Basic and diluted loss per ordinary share	$ (0.06)	$ (0.03)	$ (0.04)
Diluted earnings (loss) per share	$ (0.06)	$ (0.03)	$ (0.04)

COMMITMENTS AND CONTINGENT LI_2

COMMITMENTS AND CONTINGENT LIABILITIES (Details) ₪ in Millions				12 Months Ended
	Jan. 05, 2023 ILS (₪)	Jan. 05, 2023 USD ($)	Dec. 31, 2020	Dec. 31, 2023 USD ($)
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]
Royalties received percentage				100%
Royalties on sale			5%
Bank guarantee amount for benefit of lessor				$ 100,000
Company's outstanding open purchase order commitments				$ 6,900,000
Lawsuit claim amount	₪ 113.5	$ 32,000,000
Biokine [Member]
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]
Royalties payment percentage				20%
Maximum future milestone payments				$ 2,500,000
Value of contingent liability				$ 3,200,000
Royalties payment percentage if the company independently sell products				10%
Bottom of range [member]
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]
Percentage of net consideration received from the licensee			20%
Top of range [member]
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]
Percentage of net consideration received from the licensee			29.50%
First three years [Member]
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]
Royalties received percentage				3%
Three subsequent years [Member]
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]
Royalties received percentage				4%
Seventh year [Member]
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]
Royalties received percentage				5%

LICENSE AND SECURITIES PURCHA_2

LICENSE AND SECURITIES PURCHASE AGREEMENTS (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended	12 Months Ended
	Oct. 12, 2023	Aug. 27, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
License And Securities Purchase Agreements [Line Items]
Consideration received		$ 29,600
Costs related to share purchase agreement			$ 0	$ 762	$ 0
License Agreement [Member]
License And Securities Purchase Agreements [Line Items]
Upfront Payment	$ 15,000
Development and regulatory entitled amount	49,000
Sales milestone amount	$ 197,000
Initial royalty term	15 years
Consideration received		$ 1,417,600
Purchase Agreement [Member]
License And Securities Purchase Agreements [Line Items]
Aggregate American depositary shares		6,829,137
Purchase price per ADS		$ 2.136
Proceeds from sale or issue of treasury shares		$ 14,600
Share issue related costs		900
Consideration received		12,000
Reduction in equity		704
Share Purchase Agreement [Member]
License And Securities Purchase Agreements [Line Items]
Consideration received		1,417,600
Costs related to share purchase agreement		$ 700
SCM license [Member]
License And Securities Purchase Agreements [Line Items]
Revenue recognition			2,000
SCM support services [Member]
License And Securities Purchase Agreements [Line Items]
Revenue recognition			100
PDAC performance obligation [Member]
License And Securities Purchase Agreements [Line Items]
Revenue recognition			$ 15,500
Minimum [Member] | License Agreement [Member]
License And Securities Purchase Agreements [Line Items]
Royalties eligible margin	10%
Maximum [Member] | License Agreement [Member]
License And Securities Purchase Agreements [Line Items]
Royalties eligible margin	20%

TRANSACTIONS AND BALANCES WIT_3

TRANSACTIONS AND BALANCES WITH RELATED PARTIES (Schedule of Transactions With Related Parties) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Senior Management [Member]
Benefits to related parties:
Compensation and benefits to management, including benefit component of equity instrument grants	$ 3,155	$ 2,968	$ 2,302
Director [Member]
Benefits to related parties:
Compensation and benefits to management, including benefit component of equity instrument grants	$ 587	$ 507	$ 300

TRANSACTIONS AND BALANCES WIT_4

TRANSACTIONS AND BALANCES WITH RELATED PARTIES (Schedule of Key Management Compensation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of transactions between related parties [abstract]
Salaries and other short-term employee benefits	$ 2,425	$ 2,298	$ 1,883
Post-employment benefits	256	131	136
Other long-term benefits	31	35	35
Share-based compensation	1,030	1,011	548
Benefits to key executive personnel	$ 3,742	$ 3,475	$ 2,602

SUPPLEMENTARY FINANCIAL STATE_3

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Other Receivables) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Disclosure of supplementary financial statement information [Abstract]
Advance payments	$ 480	$ 0
Government institutions	245	687
Other	105	34
Other receivables	$ 830	$ 721

SUPPLEMENTARY FINANCIAL STATE_4

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Accounts Payable and Accruals) (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Accounts payable:
Overseas	$ 7,704	$ 6,061
In Israel	3,165	905
Trade	10,869	6,966
Other:
Payroll and related expenses	2,184	931
Accrued expenses	662	352
Accrual for vacation and recreation pay	419	377
Other	88	84
Other	$ 3,353	$ 1,744

SUPPLEMENTARY FINANCIAL STATE_5

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Revenues) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of supplementary financial statement information [Abstract]
License revenues	$ 4,610	$ 0	$ 0
Product sales, net	190	0	0
REVENUES	$ 4,800	$ 0	$ 0

SUPPLEMENTARY FINANCIAL STATE_6

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Cost of revenues) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of supplementary financial statement information [Abstract]
Cost related to license revenues	$ 3,230	$ 0	$ 0
Depreciation and amortization	450	0
Cost of product sales	12	0	0
COST OF REVENUES	$ (3,692)	$ 0	$ 0

SUPPLEMENTARY FINANCIAL STATE_7

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Research and Development Expenses) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of supplementary financial statement information [Abstract]
Research and development services	$ 4,603	$ 9,296	$ 12,088
Payroll and related expenses	4,452	4,495	4,074
Lab, occupancy and telephone	969	902	882
Professional fees	935	954	595
Share based compensation	760	1,198	971
Depreciation and amortization	583	615	660
Other	217	169	196
Research and development expenses	$ 12,519	$ 17,629	$ 19,466

SUPPLEMENTARY FINANCIAL STATE_8

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Sales and Marketing Expenses) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of supplementary financial statement information [Abstract]
Payroll and related expenses	$ 8,868	$ 947	$ 308
Medical Affairs	4,824	1,316	0
Marketing	4,091	1,805	700
Office related expenses	1,923	519	0
Market Access	1,606	1,023	0
Business Analytics	1,005	106	0
Travel	986	84	25
Sales And Marketing Share Based Compensation	751	112	(59)
Sales And Marketing Professional Fees	745	521	0
Sales And Marketing Depreciation And Amortization	314	0	0
Sales And Marketing Expenses Other	158	29	29
Sales and marketing expenses	$ 25,270	$ 6,462	$ 1,003

SUPPLEMENTARY FINANCIAL STATE_9

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of General and Administrative Expense) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of supplementary financial statement information [Abstract]
Payroll and related expenses	$ 2,117	$ 1,706	$ 1,408
Professional fees	2,028	1,248	1,103
Insurance	939	1,046	1,064
Share based compensation	780	895	583
Depreciation	37	39	42
Other	409	132	108
General and administrative expenses	$ 6,310	$ 5,066	$ 4,308

SUPPLEMENTARY FINANCIAL STAT_10

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Non-Operating Income (Expenses), Net) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of supplementary financial statement information [Abstract]
Changes in fair value of warrants	$ (11,054)	$ 6,425	$ (1,936)
Issuance costs	0	(762)	0
Other	235	7	106
Non-operating income, net	$ (10,819)	$ 5,670	$ (1,830)

SUPPLEMENTARY FINANCIAL STAT_11

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Financial Income) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of supplementary financial statement information [Abstract]
Interest income	$ 2,007	$ 694	$ 277
Exchange differences, net	61	0	282
Financial income	$ 2,068	$ 694	$ 559

SUPPLEMENTARY FINANCIAL STAT_12

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Financial Expenses) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of supplementary financial statement information [Abstract]
Interest expense	$ 2,144	$ 1,786	$ 984
Exchange differences, net	0	346	0
Bank commissions	25	26	22
Financial expenses	$ 2,169	$ 2,158	$ 1,006